

(19)



(11)

EP 2 392 352 A2

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art. 153(4) EPC

(43) Date of publication:

07.12.2011 Bulletin 2011/49

(51) Int Cl.:

A61K 39/395 ^(2006.01) **A61K 31/7105** ^(2006.01)
G01N 33/53 ^(2006.01) **A61P 29/00** ^(2006.01)
A61P 37/08 ^(2006.01)

(21) Application number: **10735985.3**

(86) International application number:
PCT/KR2010/000315

(22) Date of filing: **18.01.2010**

(87) International publication number:
WO 2010/087594 (05.08.2010 Gazette 2010/31)

(84) Designated Contracting States:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

- **CHOI, Hye In**
Daejeon 302-836 (KR)
- **SOHN, Myung-ho**
Daejeon 300-739 (KR)
- **KIM, Ho youn**
Seoul 138-737 (KR)
- **CHO, Mi-La**
Seoul 137-040 (KR)
- **JANG, Young-Soon**
Daejeon 305-721 (KR)
- **MOON, Ji-Hun**
Daejeon 306-060 (KR)
- **PARK, Ji Hyun**
Haman-gun
Gyeongsangnam-do 637-921 (KR)

(30) Priority: **28.01.2009 KR 20090006592**

30.11.2009 KR 20090116723

(71) Applicant: **Korea Research Institute of Bioscience and Biotechnology**

Daejeon 305-806 (KR)

(72) Inventors:

- **PARK, Young Woo**
Daejeon 305-762 (KR)
- **JEON, Jae Won**
Daejeon 305-744 (KR)
- **JUNG, Joon-Goo**
Daejeon 302-814 (KR)

(74) Representative: **Fleck, Barbara**
Marks & Clerk LLP
62-68 Hills Road
Cambridge
CB2 1LA (GB)

(54) **CD93 OR USE OF SOLUBLE FRAGMENT THEREOF**

(57) The present invention relates to an anti-inflammatory composition using the antibody specifically binding to CD93 or its soluble fragment, and a diagnostic method and a diagnostic kit for inflammatory disease using CD93 or its soluble fragment specific antibody or aptamer.

[Fig. 1]

A

```

1 MATSMGLLLL LLLLLTPGA GTGADTEAVV CVGTACYTAH SGKLSAAEAQ NHCNQNGGNL
61 ATVKSKEEAQ HVQRVLAQLL RREAALTARM SKFWIGLQRE KGKCLDPSLP LKGFVWVG
121 EDTPYSNWFH ELRNSCISKR CVSLLDLSQ PLLPSRLPKW SEGPGSPGS PGSNIEGFVC
181 KFSFKGMCRP LALGGPGQVT YTPFPQTTSS SLEAVPASA ANVACGEGDK DETQSHYFLC
241 KEKAPDVFVW GSSGGLCVSP KYGKNFYNGG CHQDCFEQD GSFVCGCRPG FRLLDVLVTC
301 ASRNPCSSSP CRGGATCVLG PHGKNYTCRC PQGYQLDSSQ LDCVVDDECQ DSPCAQECVN
361 TPGGFRCECW VGYEGGGPGE GACQDVDECA IGRSPCAQGC TINTDGSFHCS CEEGYVLAGE
421 DGTQCQDVDE CVGPGGPLCD SLCFNTQGSF HCGCLPGWVL APNGVSTMG PVS LGPPSPG
481 PDEEDXGEKE GSTVPRATA SPTRGPEGTP KATPTTSPS LSSDAPITSA PLXMLAPSGS
541 PGVWREPSIH HATAASGPQE PGGDSSVAT QNINDGTDGQK LLLFVILGTV VALLLLALA
601 LGLLVYRKRK AKREEKKEK PQNAADSYSW VPERAESRAM ENQYSPPTGT DC

```

B

```

24GTGADTEAVV CVGTACYTAHSGKLSAAEAQ NHCNQNGGNL ATVKSK
EEAQHVQRVLAQLL RREAALTARMSKFWIGLQREKGKCLDPSLP LKGF
WVGGEDTPYSNWFH KEKAPDVFVW GSSGGLCVSP KYGKNFYNGG
CGSPGSPGSNIEGFVCKFSFKGMCRPLALGGPGQVTYTPFPQTTSSSLEA
VPFASAAANVACGEGDKDETQSHYFLCKEKAPDVFVW GSSGGLCVSPKY
GCNFNNGGCHQDCFEQD GSFVCGCRPGFRLLDVLVTCASRNPCSSSP
CRGGATCVLGHGKNYTCRC PQGYQLDSSQLDCVD245

```

EP 2 392 352 A2

Description

[Technical Field]

5 **[0001]** The present invention relates to an anti-inflammatory composition, a diagnostic method and a diagnostic kit for inflammatory disease prepared by using antibody specifically binding to CD93 or soluble fragment of the same.

[Background Art]

10 **[0002]** Human CD93 (C1qRp, AA4.1(mouse)) is type 1 transmembrane glycoprotein located on chromosome 20, p11.21 (Malhotra, R. et al., 1993. *Immunology* 78: 341-348; Nepomuceno, R. R. et al., 1997. *Immunity* 6: 119-129; Steinberger, P. et al., 2002. *Biol.* 71: 133-140). According to the previous reports, this protein is involved in cell-cell interaction during B cell development and phagocytosis (Petrenko, O. et al., 1999. *Immunity* 10: 691-700; Norsworthy, P. J. et al., 2004. *J. Immunol.* 172: 3406-3414; Nepomuceno, R. R. et al., 1997. *Immunity* 6: 119-129; McGreal, E. P. et al., 2002. *J. Immunol.* 168: 5222-5232).

15 **[0003]** CD93 is composed of 652 amino acids including leader sequence, c-type carbohydrate-sensing domain, 5 EGF-like domains, mucin domain, one transmembrane domain, and intracellular domain of 47 amino acids (Nepomuceno R. R. et al., 1997. *Immunity* 6:119-129; Park, M. et al., 2003. *J. Cell Physiol.* 196: 512-522; Nepomuceno, R. R. et al., *J. Immunol.* 162:3583). CD93 is expressed in myeloid lineages, hematopoietic stem cells, NK cells, platelets, microglia, and endothelial cells, etc (Nepomuceno, R. R. et al., 1997. *Immunity* 6:119; Nepomuceno, R. R. et al., 1998. *J. Immunol.* 160:1929; Danet G. H. et al., *Proc Natl Acad Sci USA* 2002; 99:10441-5; Lovik G. et al., *J Immunol* 2000; 30:3355-62; Fonseca M. I. et al., *J Leukoc Biol* 2001; 70:793-800; Webster, S. D. et al., 2000. *J. Leukocyte Biol.* 67:109). A previous report stated that CD93 was not expressed in tissue macrophages but expressed in vascular endothelial cells in a large scale (Petrenko, O. et al., 1999. *Immunity* 10:691; Dean, Y. D. et al., *J. Immunol.* 31:1370; Fonseca, M. 1. et al., 2001. *J. Leukocyte Biol.* 70:793.). CD93 was presumed to be involved in C1q-mediated enhancement of phagocytosis, according to a research using anti-CD93 antibody, suggesting that CD93 might be acting as C1q receptor. However, consequent experiments proved that CD93 did not bind directly to C1q (Nepomuceno, R. R. et al. 1999. *J. Immunol.* 162:3583; McGreal, E. P. et al., 2002. *J. Immunol.* 168:5222; Steinberger, P. et al., 2002. *J. Leukocyte Biol.* 71:133).

20 **[0004]** In the experiment with CD93 knock-out mouse, a problem in eliminating killed cells was caused by the absence of CD93. However, in the in vitro experiment, no functional abnormality was observed (Guan, E. et al., 1994. *J. Immunol.* 152: 4005-4016; Norsworthy, P. J. et al., 2004. *J. Immunol.* 172: 3406-3414; Norsworthy, P. J. et al., 2004. *J. Immunol.* 172: 3406-3414). Phagocytosis plays an important role in the early stage of immune response, that is the function is very important in eliminating killed cells (Brown, E. J. (1995) *Phagocytosis. Bioessays* 17, 109-117).

25 **[0005]** Recent studies provided some clues to answer the questions about such functions. For example, it has been reported that shedding of CD93 occurs in the pro-inflammatory state of TNF- α and LPS, etc., so that ectodomain of CD93 is cut off (Park, M. et al., 2003. *J. Cell Physiol.* 196: 512-522.; Suzanne S. Bohlson et al., 2005. *J. immunol.* 175: 1239-1247). It has also been reported that CD93 is fragmented into soluble fragments in U937 cells by the treatment of PMA (phorbol-12-myristate-13-acetate) (Ikewaki N., Tamauchi H., and Inoko H. 2007. Decrease in CD93 expression in a human monocyte-like cell line (U937) treated with various apoptosis-inducing chemical substances. *Microbiol. Immunol.*, 51(12):1189-1200). Besides, WO 2008/082519 states that CD93-related polymorphs are very useful for the diagnosis of type-1 diabetes and Lupus Erythematosus. However, there have no reports made yet about the use of CD93 for the treatment or diagnosis of inflammatory disease.

30 **[0006]** Thus, the present inventors studied the possibility of the involvement of CD93 or its soluble fragment in inflammation. As a result, the present inventors confirmed that a soluble fragment of CD93 has excellent anti-inflammatory effect and CD93 or its soluble fragment is over-expressed in the presence of inflammation inducing substances or inflammatory environment, so that the inventors further completed this invention by proving that a soluble fragment of CD3 can be used as an active ingredient of an anti-inflammatory composition and CD93 or a soluble fragment thereof can also be used as a diagnostic marker for inflammatory disease.

50 [Disclosure]

[Technical Problem]

55 **[0007]** It is an object of the present invention to provide an anti-inflammatory composition prepared by using soluble fragment of CD93.

[0008] It is another object of the present invention to provide a diagnostic kit for inflammatory disease and a diagnostic method for inflammatory disease using CD93 or soluble fragment of the same.

[Technical Solution]

[0009] To achieve the above objects, the present invention provides an anti-inflammatory composition containing antibody specific to the soluble fragment of CD93 composed of the amino acid sequence represented by SEQ. ID. NO: 1 as an active ingredient.

[0010] The present invention also provides an anti-inflammatory composition containing one or more substances selected from the group consisting of siRNA, shRNA, and shRNA expression vector capable of suppressing the expression of CD93 gene composed of the nucleotide sequence represented by SEQ. ID. NO: 4 as an active ingredient.

[0011] The present invention further provides a method for treating inflammation containing the step of administering the said composition to a subject having inflammation.

[0012] The present invention also provides a method for preventing inflammation containing the step of administering the said composition to a subject.

[0013] The present invention also provides a diagnostic kit for inflammatory disease containing antibody or aptamer specifically binding to CD93 or soluble fragment of the same.

[0014] In addition, the present invention provides a diagnostic method for inflammatory disease using the said diagnostic kit for inflammatory disease.

[Advantageous Effects]

[0015] As explained hereinbefore, the present invention can provide an anti-inflammatory composition containing antibody specific to the soluble fragment of CD93 as an active ingredient, and the said composition can be effectively used for the prevention or treatment of inflammatory disease. The present invention can also provide a use of CD93 or its soluble fragment as a diagnostic marker for inflammatory disease, and this marker can be effectively used for diagnosis or monitoring of inflammatory disease

[Brief Description of the drawings]

[0016] The application of the preferred embodiments of the present invention is best understood with reference to the accompanying drawings, wherein:

Figure 1 is a set of diagrams showing the amino acid sequence of full length CD93 protein (Figure 1A) and the amino acid sequence of sCD93 protein (Figure 1B).

Figure 2 is an electrophoresis photograph illustrating sCD93_Fc expressed in HEK293E cells and purified thereafter. Herein, N indicates non-reduced protein and R indicates reduced protein.

Figure 3 - Figure 6 illustrate the differentiation of THP-1 cells into macrophages induced by sCD93.

Figure 3 is a set of photographs illustrating the adherence of THP-1 cells on the surface of dish.

Figure 4 is a graph illustrating the adherence rate of THP-1 cells.

Figure 5 is a set of photographs illustrating the differentiation of THP-1 cells into macrophages.

Figure 6 is a set of graphs illustrating the expressions of macrophage differentiation markers.

Figure 7 - Figure 11 illustrate the effect of sCD93 protein on MAPK signal activation.

Figure 7 is a set of electrophoresis photographs illustrating the quantification of phospho-Erk 1/2, phospho-p38 and whole p38 by Western blotting.

Figure 8 is a set of electrophoresis photographs illustrating the quantification of phospho-Erk 1/2 over the treatment time of sCD93 protein.

Figure 9 is a set of graphs illustrating the expressions of TNF- α and IL-6 measured at RNA level after the treatment of sCD93 protein.

Figure 10 is a set of graphs illustrating the expressions of IL-1 β and iNOS measured at protein level after the treatment of sCD93 protein.

Figure 11 is a set of graphs illustrating the expressions of IL-12, CXCL12, SPHK-1 and CLEC4A measured at protein level after the treatment of sCD93 protein.

Figure 12 is a graph illustrating the expression of TNF- α measured at protein level after the treatment of sCD93 protein.

Figure 13 is an electrophoresis photograph illustrating the effect of sCD93 protein on the expression of matrix metalloprotease (MMP).

Figure 14 is a set of photographs illustrating the inducing effect of sCD93 protein on phagocytosis.

Figure 15 is a FACS graph illustrating the inducing effect of sCD93 protein on phagocytosis.

Figure 16 is a graph illustrating the inhibitory effect of anti-CD93 antibody on the production of TNF- α .

Figure 17 is a graph illustrating the inhibitory effect of CD93 siRNA on the productions of TNF- α and IL-6.

Figure 18 is a set of graphs illustrating the expression of CD93 on the cell surface after treating THP-1 cells (human

mononuclear cells) with LPS, TNF- α or PMA, measured by FACS.

Figure 19 is a set of photographs illustrating the expressions of CD93 and its soluble fragment on the cell surface after treating THP-1 cells with LPS, TNF- α or PMA, measured by Western blotting.

5 Figure 20 is a graph illustrating the expression of CD93 mRNA on the cell surface after treating THP-1 cells with LPS or PMA, measured by RT-PCR.

Figure 21 is a graph illustrating the expression of mouse CD93 in peritoneal macrophages after injecting PBS, thioglycollate or LPS to a mouse, analyzed by FACS.

Figure 22 is a set of photographs illustrating the expressions of mouse CD93 in PBMC and peritoneal macrophages after injecting PBS, thioglycollate or LPS to a mouse, observed by Western blotting.

10 Figure 23 is a graph illustrating the amount of mouse CD93 soluble fragment in serum and peritoneal lavage fluid after injecting PBS, thioglycollate or LPS to a mouse, measured by sandwich ELISA.

Figure 24 is a set of photographs illustrating the expression of CD93 in synovial membrane tissue obtained from a patient with rheumatoid arthritis (RA) or degenerative arthritis (OA), analyzed by immunohistochemical technique after staining the tissue with anti-CD93 antibody.

15 Figure 24 is a graph illustrating the amount of CD93 soluble fragment in synovial fluid obtained from a patient with rheumatoid arthritis (RA) or degenerative arthritis (OA), measured by sandwich ELISA.

[Best Mode]

20 **[0017]** Hereinafter, the present invention is described in detail.

[0018] The present invention provides an anti-inflammatory composition containing antibody specific to sCD93, the soluble fragment of CD93, as an active ingredient.

[0019] The present invention also provides a use of the antibody specific to sCD93, the soluble fragment of CD93, for the preparation of the anti-inflammatory composition.

25 **[0020]** The present inventors confirmed that THP-1 cells were differentiated into macrophages mediated by the activation of mitogen-activated protein kinase (MAPK), phagocytosis was induced, secretion of inflammatory cytokines such as TNF- α , IL-1 β , and IL-6 was increased, and secretion of matrix metalloproteinase (MMP) was accelerated, when THP-1 (human derived mononuclear cell line) was treated with sCD93.

30 **[0021]** The said MAPK is activated by inflammation inducing substances such as bacterial lipopolysaccharides, etc. Once it is activated, it accelerates the secretion of inflammatory cytokines. So, the secretion of MMP is accelerated in the process of inflammation response.

[0022] Considering such inflammation response inducing effect of sCD93, the present inventors studied and confirmed that the cytokine TNF- α known to be generated primarily by activated mononuclear cells or macrophages was decreased when THP-1 cells were treated with anti-sCD93 antibody.

35 **[0023]** The present invention has been built based on the result of the experiment proving the statement above. Therefore, the anti-inflammatory composition of the present invention characteristically contains sCD93 specific antibody as an active ingredient.

40 **[0024]** In this description, "sCD93" indicates the soluble fragment of CD93 which is fallen apart from the whole CD93, and the amino acid sequence and nucleotide sequence of the fragment are shown in <Figure 1B> and represented by <SEQ. ID. NO: 1 and NO:2>. In this description, the target protein indicates sCD93, unless stated otherwise. The sequence of total length CD93 is shown in <Figure 1A> and represented by <SEQ. ID. NO: 3>. The nucleotide sequence of the gene of the protein is represented by <SEQ. ID. NO: 4>.

[0025] In this description, "anti-inflammatory" indicates prevention, improvement, treatment, and delay of inflammatory disease.

45 **[0026]** In this description, the said "inflammatory disease" indicates any state defined by local or systemic defense response against infection with foreign infectious agents such as physical or chemical stimuli, bacteria, fungi, virus, and various allergens, etc. This response accompanies a series of complicated physiological responses including activation of various inflammatory mediators and immune cell related enzymes (iNOS, COX-2, etc), secretion of inflammatory mediators (NO, TNF- α , IL-6, IL-1 β , and PGE₂), infiltration of body fluid, cell migration, tissue destruction, etc, and is shown
50 as such symptoms as erythema, pain, edema, pyrexia, functional deficiency or loss, etc. The said inflammatory disease can be acute, chronic, ulcerative, allergenic, or necrotic, so if a disease is defined as inflammatory disease, it does not matter whether it is acute, chronic, ulcerative, allergenic, or necrotic. Particularly, the inflammatory disease herein is exemplified by asthma, allergic and non-allergic rhinitis, acute and chronic rhinitis, acute and chronic gastritis or enteritis, ulcerative gastritis, acute and chronic nephritis, acute and chronic hepatitis, chronic obstructive pulmonary disease, pulmonary fibrosis, irritable bowel syndrome, inflammatory pain, migraine, headache, lumbago, fibromyalgia, myofascial disease, viral infection (hepatitis C virus), bacterial infection, fungal infection, burn, wound by surgical or dental operation,
55 hyper-prostaglandin E syndrome, atherosclerosis, gout, arthritis, rheumatoid arthritis, ankylosing spondylitis, Hodgkin's disease, pancreatitis, conjunctivitis, iritis, scleritis, uveitis, dermatitis, eczema, and multiple sclerosis, etc.

[0027] In this description, "an active ingredient" indicates an ingredient that is active by itself or with a pharmaceutically acceptable non-active carrier. The meaning of "pharmaceutically acceptable" is explained hereinafter.

[0028] In this description, "specific binding" indicates that antibody is conjugated with its target protein sCD93 to produce antigen-antibody complex but is not practically conjugated with any other proteins. Herein, "practically" means it can produce a non-specific conjugate with low chance, yet. Herein, "specific binding" can also be described as the binding that can be determined by antigenic determinant site, the specific protein structure called epitope.

[0029] In this description, "epitope" indicates the amino acid region (antigen determinant site) having antigenicity or immunogenicity in sCD93, the target protein. Epitope generally includes at least 10 amino acids. The epitope can be identified by the conventional method, such as phage display and reverse immunogenetics, which have been well-informed to those in the art.

[0030] In this description, "antibody" includes every kinds that can be specifically bind to sCD93, the target protein, which is exemplified not only by monoclonal antibody, polyclonal antibody, multispecific antibody (antibody that has specificity against at least two or more antigens or epitopes, ex, bispecific antibody), humanized antibody, human antibody, but also by antibody fragment, recombinant antibody, and chemically modified antibody that are able to bind specifically to sCD93, the target protein.

[0031] The humanized antibody indicates the antibody in which complementarity determining region (CDR) of human immunoglobulin is substituted with non-human CDR such as CDR of mouse, rabbit, rat, and apes, so as to minimize immunorejection. The preparation method of such antibody has been well-informed to those in the art. Details can be found in the following references (Riechmann L. et al., *Nature*, 332: 323-327, 1988; Nakatani T. et al., *Protein Engineering*, 7: 435-443, 1994; Jones et al., *Nature*, 321: 522-525, 1986; Presta, *Curr. Op. Struct. Biol.*, 2: 593-596, 1992).

[0032] The human antibody indicates the antibody obtained from an animal immunized with a specific antigen. In the animal such as mouse, the gene responsible for producing endogenous immunoglobulin has been destroyed and human immunoglobulin gene is inserted therein. Details can be found in the following references (Jakobovits et al., *Proc. Natl. Acad. Sci. USA*, 90: 2551, 1993; Jakobovits et al., *Nature*, 362: 255-258, 1993; Bruggermann et al., *Year in Immuno.*, 7: 33, 1993; Hoogenboom et al., *J. Mol. Biol.*, 227: 381, 1991; Marks et al., *J. Mol. Bio.*, 222: 581-597, 1991).

[0033] The antibody fragment herein is exemplified by Fab, F(ab'), F(ab')₂, scFv (antibody whose Fv of heavy chain or light chain is connected by a proper linker), Fv fragment, Fab/c (antibody having one Fab and complete Fc), linear antibody (Zapata et al., *Protein Eng.* 8(10):1057-1062(1995)), antibody fragments obtained by treating antibody with protease such as papain and pepsin, and those antibody fragments obtained by genetic recombination technique characterized by introduction of gene corresponding to the fragment to host cells and expression therein. Globulin type of the said antibody is not limited as long as it can be specifically bound to the target protein sCD93, which can be selected from the group consisting of IgG, IgM, IgA, IgE, IgY, and IgD.

[0034] In the meantime, the polyclonal antibody can be prepared by immunizing such animal as birds (for example, fowl, etc), and mammals (for example, rabbit, goat, horse, sheep, rat, non-human apes like monkey, chimpanzee, and gorilla) with sCD93, the target protein. In general, antibody titer is measured by enzyme immunoassay (EIA and ELISA) or radioimmunoassay (RIA) after 6 - 60 days from the final immunization. When the antibody titer reaches the peak, blood work is performed. Antibody is purified from the blood sample by the conventional method such as ion exchange chromatography and affinity chromatography, etc.

[0035] The monoclonal antibody can be obtained from the hybridoma cell line producing sCD93 specific monoclonal antibody. To generate such hybridoma cell line, an animal (for example, mouse) is immunized with the target protein sCD93, and then spleen cells are extracted from the immunized animal. The spleen cells are fused with myeloma cells, leading to the production of hybridoma cells. Finally, the hybridoma cell line producing monoclonal antibody is identified. Isolation or recovery of monoclonal antibody from the hybridoma cell line can be performed by the conventional method well-informed to those in the art.

[0036] The preparation of the monoclonal antibody is described in detail hereinafter.

[0037] First, to obtain the monoclonal antibody, the target protein sCD93 is administered to mammals, for example, rat, mouse, rabbit, monkey, goat, and non human apes (monkey, chimpanzee, and gorilla), etc. One time dose of immunogen is determined by those in the art with considering the kind of test animal, administration pathway, etc, which should be appropriate and generally acceptable. In general, one-time dose can be 50 - 200 μ g per animal. For the administration, immunogen is diluted with or suspended in PBS (phosphate-buffered saline) or saline, which is then mixed with a proper adjuvant. After emulsification, it is administered hypodermically or intraperitoneally. Administration is preferably performed 2 - 10 times at a few days or a few weeks intervals, more preferably 1 - 4 weeks intervals, and most preferably 3 - 4 times at that intervals. During the administration, antibody titer of the immunized animal serum is measured by ELISA. When the antibody titer reaches plateau, the immunogen is administered intravenously or intraperitoneally one last time. After 2 - 5 days from the final administration, antibody producing cells are collected. The antibody producing cells can be exemplified by spleen cells, lymph node cells, peripheral blood cells, etc, but spleen cells or lymph node cells are preferred.

[0038] After collecting antibody producing cells, hybridoma cell line producing the monoclonal antibody specific to the

target protein sCD93, the immunogen introduced therein, is constructed. Such hybridoma cell line can be produced and identified by the conventional method well-informed to those in the art. In general, antibody producing cells, preferably spleen cells are extracted from the immunized animal, and then the extracted spleen cells are fused with myeloma cells to construct hybridoma cells, followed by identification of the hybridoma cell line producing monoclonal antibody specifically binding to the immunogen. As the myeloma cell line used for fusion with the antibody producing cells, the cell line originated from an animal such as a mouse can be used. Such cell line can also be purchased. The preferable myeloma cell line is the one originated from the animal which is the same line of the immunized animal, has drug selectivity to antibiotics, etc, and cannot survive in HAT selection medium containing hypoxanthine, aminopterin, and thymine without being fused with spleen cells, but only can survive as being fused with spleen cells. The myeloma cell line is exemplified by P3X63 (ATCC TIB9), the HGPRT⁻ (hypoxanthine guanine phosphoribosyl-transferase negative) cell line originated from BALB/c mouse.

[0039] The fusion of antibody producing spleen cells with myeloma cell line is performed in serum-free DMEM or RPMI-1640 at a proper ratio (1:1 - 20:1) in the presence of cell fusion accelerator. As the cell fusion accelerator, poly ethylene glycol (average molecular weight: 1500 - 4000) can be used at the concentration of 10 - 80%. To increase fusion efficiency in some cases, such adjuvant as dimethylsulfoxide can be added. Or commercial cell fusion device can also be used for the fusion.

[0040] After cell fusion, target hybridoma is selected. In general, cell suspension is properly diluted with RPMI-1640 supplemented with FBS, followed by distribution on micro-titer plate at the density of 20,000 cells per well. Selection medium is added to each well and the medium is replaced with the same selection medium properly to provide fresh medium for culture. Preferable culture temperature is 20 - 40°C. When the myeloma cell line is HGPRT deficient or thymidine kinase deficient cell line, the selection medium containing hypoxanthine, aminopterin and thymidine (HAT medium) is used to culture and proliferate hybridoma cells of antibody producing cells and myeloma cell line selectively. Approximately around 14 days from beginning of the culture in such selection medium, hybridoma cells can be obtained. Target antibody is screened with the supernatant of the growing hybridoma culture solution. The screening can be performed by the conventional method well-known to those in the art. For example, enzyme immunoassay (EIA and ELISA) and radioimmunoassay, etc can be used. Cloning of fused cell can be performed by limiting dilution method.

[0041] The cloned hybridoma is cultured in animal cell culture medium such as RPMI-1640 containing 10% FBS, DMEM, or serum-free medium under the conventional culture condition (For example, 37 °C, 5% CO₂). Duration of culture is preferably 2 - 10 days. Monoclonal antibody can be obtained from the supernatant of the culture solution.

[0042] Collection of monoclonal antibody can be performed by the conventional method well-known to those in the art, which is selected from the group consisting of ammonium sulfate fractionation, ion exchange chromatography, affinity chromatography, gel filtration chromatography, and combinations of those.

[0043] For the production of the monoclonal antibody of the present invention, genetic recombination technique, that is the process comprising cloning antibody gene from hybridoma; introducing the gene into a proper vector; transfecting host cells with the vector; and expressing the gene, can be used (Vandamme, A. M. et al., Eur. J. Biochem., 192, 767-775, 1990).

[0044] Particularly, mRNA encoding variable region (V region) of the antibody of the present invention is obtained from the hybridoma producing the antibody of the invention. Total RNA is obtained by the conventional method well-informed to those in the art such as guanidine ultracentrifugation (Chirgwin, J. M. et al., Biochemistry., Vol 18, 5294-5299, 1979) and AGPC (Chomczynski, P. et al., Anal. Biochem., 162, 156-159), etc. Then, target mRNA is obtained from the total RNA by using mRNA purification kit (Pharmacia). As an alternative, QuickPrep mRNA purification kit (Pharmacia) can also be used to obtain mRNA directly.

[0045] From the obtained mRNA, cDNA of variable region of the antibody is synthesized by using reverse transcriptase. If necessary, RACE PCR can be used for cDNA synthesis or amplification. The synthesized cDNA encoding variable region is introduced into an expression vector comprising DNA encoding constant region (C region). This expression vector can contain regulatory sequence such as promoter, enhancer, replication origin, polyadenylation signal, and ribosome binding site, etc. Once host cells are transformed with this expression vector, they can produce antibody. For the expression of antibody gene, DNA encoding antibody heavy chain (H chain) or light chain (L chain) is inserted in the expression vector respectively to transform host cells. Or it is still possible to introduce DNA encoding heavy chain and light chain in the expression vector to transform host cells (WO 94/11523).

[0046] The immunogen used for the production of antibody of the present invention, that is the target protein of the invention sCD93, can be prepared by the conventional genetic recombination technique well-known to those in the art. In general, cDNA of the target protein sCD93 is constructed, which is then inserted in an expression vector. Prokaryotic or eukaryotic host cells are transformed with the expression vector, which are then cultured in proper medium. Then, the target protein is obtained from the culture solution or cultured cells. The said cDNA can be constructed by the conventional method based on gene sequences provided by gene/protein database such as GenBank, etc or sequences provided by this description.

[0047] For the construction of cDNA, DNA synthesizer using phosphoramidite, RT-PCR, or hybridization using cDNA

library can be used. If necessary, target cDNA can be amplified by PCR.

[0048] The expression vector herein can be purchased from one of biotech companies such as Novagen, Dakara Shuzo, Qiagen, Stratagene, Promega, Roche Diagnostics, Invitrogen, and Genetics Institute, etc.

[0049] Such expression vector can include control elements such as promoter, enhancer, polyadenylation signal, ribosome binding site, replication origin, terminator, selection marker, and marker peptide sequence for deletion or purification (for example, nucleotide sequence encoding histidine repeats), in addition to DNA encoding the target protein sCD93.

[0050] As the host cells, prokaryotic cells including bacteria (for example, *E. coli* and *Bacillus subtilis*) and eukaryotic cells including yeast (for example, *Saccharomyces cerevisiae*), insect cells (for example, sf cells), mammalian cells (for example, COS, CHO, BHK), etc can be used.

[0051] For the purification of the target protein of the present invention from host cells or culture solution thereof, ultrafiltration, gel filtration, ion exchange chromatography, affinity chromatography (if marker peptide is conjugated), HPLC, hydrophobic chromatography, isoelectric chromatography, or their combinations can be used.

[0052] Production of the target protein of the present invention based on DNA recombination technique is referred to the following references (Sambrook et al, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory Press, US(1989); Ausubel et al, Current Protocols in Molecular Biology, Jon Willey & Sons, US(1993); and Sambrook, J. & Russel, D., Molecular Cloning, A LABORATORY MANUAL, Cold Spring Harbor Laboratory Press, 1:7.42-7.45, 2: 8.9-8.17, 2001). Those references are considered as a part of this description.

[0053] As the immunogen used for the production of antibody of the present invention, sCD93 fragment or total length CD93 can be used because antibody obtained by using either fragment or full-length protein is capable of being bound specifically to the target protein of the present invention.

[0054] The present invention also provides an anti-inflammatory composition containing one or more substances selected from the group consisting of siRNA, shRNA, and shRNA expression vectors capable of suppressing the expression of CD93 gene composed of the nucleotide sequence represented by SEQ. ID. NO: 4 as an active ingredient.

[0055] The present invention further provides a use of one or more substances selected from the group consisting of siRNA, shRNA, and shRNA expression vectors capable of suppressing the expression of CD93 gene for the production of an anti-inflammatory composition.

[0056] The present inventors confirmed that inflammatory cytokines such as TNF- α and IL-6 which are increased usually by the treatment of LPS (lipopolysaccharide) were down-regulated when siRNA against CD93 gene was treated to THP-1.

[0057] When siRNA (small interfering RNA) or shRNA (short hairpin RNA) which are gene specific short double stranded RNAs are introduced in cells, they are processed by ribonuclease dicer to be bound to RISC (RNA induced gene silencing complex) to induce RNAi (Nature 391, 806-811, 1998; Genes Dev. 15, 485-490, 2001; Nature 411, 494-498, 2001; Science 287, 2494-2497, 2000; Cell 101, 25-33, 2000). Helicase and endonuclease are involved in RNAi. Particularly, double stranded RNA of siRNA is untied by helicase. Antisense strand of them is bound to mRNA of target gene and the binding site is hydrolyzed by endonuclease (Cell 101, 25-33, 2000; Science 296, 1265-1269, 2002; J. Biol. Chem. 2003 Feb 28;278(9):7108-18).

[0058] In this description, "siRNA" indicates double stranded RNA comprising 10 - 40 base pairs, more preferably 15 - 30 base pairs, and most preferably 20 - 22 base pairs capable of inducing RNAi phenomenon against target gene RNA. This siRNA has either blunt end or overhang. When it has overhang, it can be both on 3' and 5' ends, but 3' end is preferred. The number of nucleotides on overhang is 1 - 5, and more preferably 2 - 3.

[0059] In this description, "shRNA" indicates hairpin structured double stranded RNA having loop region comprising 2 - 10 nucleotides. Nucleotides of the loop region can be selected as ones well-known to those in the art (Proc. Natl. Acad. Sci. USA 99(8): 5515-5520, 2002; Nature Biotechnology 20: 505-508, 2002; Nature Biotechnology 20 : 500-505, 2002; Nat Cell Biol. 5:489-490, 2003; Proc. Natl. Acad. Sci. USA 99(9):6047-6052, 2002). Constitution of double stranded region of the shRNA is same as that of the siRNA, and thus no further explanations are required.

[0060] In this description, "shRNA expression vector" indicates the vector able to express shRNA in host cells by containing shRNA coding sequence therein. The said shRNA coding sequence is composed of a part of CD93 gene, spacer sequence composing loop region, and complementary sequence to the part of CD93 gene. The shRNA coding sequence can be either RNA or DNA, depending on the expression vector to be used, and is operatively linked to regulatory sequence of the expression vector (for example, promoter, polyadenylation signal, etc). The expression vector can be plasmid vector or lentivirus vector. The plasmid vector can be purchased from one of biotech companies such as Promega (Cat. Nos. C8750, C8760, C8770, C8780, C8790, C7800, etc) and Genscript (Cat. Nos. SD1201, SD1202, SD1207, etc), or can be constructed. The use of lentivirus vector is described in WO2004/06549.

[0061] The composition of the present invention can include pharmaceutically acceptable carriers in addition to anti-sCD93 antibody, siRNA, and shRNA. Herein, "pharmaceutically acceptable" indicates that the composition has no more toxicity than applicable to a treatment subject (low and safe enough toxicity) without limiting activity of the active ingredient. Such carrier is exemplified by water, saline, dextrose, glycerol, ethanol, polyalcohol (for example, mannitol, sorbitol,

etc), and sodium chloride, etc.

[0062] The composition of the present invention can also include preservatives, anti-oxidants, wetting agents, emulsifying agents, buffers, and non-ionic surfactants to extend shelf-life or to reserve effectiveness. Proper examples of those preservatives, anti-oxidants, and wetting agents are well-informed to those in the art.

[0063] The composition of the present invention can be formulated in a variety of forms, for example, solution, suspension, syrup, tablet, pill, etc, but not always limited thereto.

[0064] The composition of the present invention can be administered orally or parenterally to mammals including human. In general, like any other bio medicines including antibody as an active ingredient, the composition of the present invention can be administered by intravenous injection, hypodermic injection, intraperitoneal injection, and intramuscular injection, but not always limited thereto.

[0065] The effective dose of the composition of the present invention can be determined by an expert in the field of medicine considering effectiveness, severity of disease, patient weight, drug formulation, administration pathway and duration, etc, but generally it is determined in the range of 0.01 $\mu\text{g}/\text{kg}/\text{day}$ - 100 $\text{mg}/\text{kg}/\text{day}$, but not always limited thereto.

[0066] The present invention also provides a diagnostic marker for inflammatory disease comprising CD93 or its soluble fragment as an active ingredient.

[0067] The said CD93 has preferably the amino acid sequence represented by SEQ. ID. NO: 33, but not always limited thereto.

[0068] The soluble fragment of CD93 is preferably the 95kDa ectodomain of CD93, the transmembrane protein, released after cell culture, but not always limited thereto.

[0069] The expression of CD93 in this invention was increased in the human mononuclear cell line THP-1 not by the treatment of PMA but by the treatment of LPS and $\text{TNF-}\alpha$. However, the amount of CD93 soluble fragment was increased by the treatment of LPS, $\text{TNF-}\alpha$, and PMA as well. After injecting PBS, thioglycollate, and LPS to a mouse, CD93 expression in mouse macrophages was confirmed to increase mostly by LPS treatment and the treatment of thioglycollate brought a similar result. The amount of CD93 soluble fragment in serum was not changed much by the treatment of LPS or thioglycollate. However, the amount of CD93 soluble fragment in peritoneal lavage fluid was significantly increased by the treatment of LPS or thioglycollate.

[0070] In the meantime, CD93 expression was significantly high in synovial membrane tissue obtained from rheumatoid arthritis patient, compared with in synovial membrane tissue obtained from osteo-arthritis patient. Consistently, the amount of CD93 soluble fragment was significantly high in synovial fluid obtained from rheumatoid arthritis patient, compared with in that in synovial fluid obtained from osteo-arthritis patient.

[0071] As explained hereinbefore, the CD93 or its soluble fragment of the present invention is up-regulated under inflammatory environment, that is in the presence of inflammation inducing substances. Therefore, the CD93 or its soluble fragment of the present invention can be effectively used as a diagnostic marker for inflammatory disease.

[0072] The inflammatory disease herein is exemplified by asthma, allergic and non-allergic rhinitis, acute and chronic rhinitis, acute and chronic gastritis or enteritis, ulcerative gastritis, acute and chronic nephritis, acute and chronic hepatitis, chronic obstructive pulmonary disease, pulmonary fibrosis, irritable bowel syndrome, inflammatory pain, migraine, headache, lumbago, fibromyalgia, myofascial disease, viral infection, bacterial infection, fungal infection, burn, wound by surgical or dental operation, hyper-prostaglandin E syndrome, atherosclerosis, gout, arthritis, rheumatoid arthritis, ankylosing spondylitis, Hodgkin's disease, pancreatitis, conjunctivitis, iritis, scleritis, uveitis, dermatitis, eczema, and multiple sclerosis, etc, but not always limited thereto.

[0073] The present invention also provides a diagnostic kit for inflammatory disease containing antibody or aptamer specifically binding to CD93 or soluble fragment of the same.

[0074] The present invention also provides a use of antibody or aptamer specifically binding to CD93 or its soluble fragment for the preparation of the diagnostic kit for inflammatory disease.

[0075] The diagnostic kit for inflammatory disease herein can be easily prepared by the conventional method well-known to those in the art using the CD93 or its soluble fragment marker of the present invention. The said aptamer is single stranded nucleic acid (DNA, RNA or modified nucleic acid) characterized by the stable tertiary structure, high affinity to target molecule, and specificity to target.

[0076] The diagnostic kit for inflammatory disease herein can include antibody specifically binding to CD93 or its soluble fragment, secondary antibody conjugate conjugated with a marker colored by reaction with substrate, chromogenic substrate solution to respond with the marker, washing solution, and enzyme reaction terminating solution, etc.

[0077] The present invention also provides a diagnostic method for inflammatory disease using the CD93 or its soluble fragment marker of the present invention.

[0078] Particularly, the said method is preferably performed by the following steps, but not always limited thereto:

- 1) coating biological sample and control protein on a fixture;
- 2) inducing antigen-antibody reaction by adding the antibody specifically binding to CD93 or its soluble fragment, the diagnostic marker for inflammatory disease, to the above fixture;

- 3) detecting the antigen-antibody reaction product produced by the above antigen-antibody reaction by using a secondary antibody conjugate marker and chromogenic substrate solution; and
 4) comparing the detection results between the biological sample and the control.

[0079] The biological sample herein is preferably one or more materials selected from the group consisting of tissue, cell, blood, serum, peritoneal lavage fluid, synovial fluid, saliva, urine, and feces, but not always limited thereto.

[0080] In the above method, the secondary antibody conjugate marker is preferably the conventional coloring agent appropriate for color development, which is exemplified by such fluoresceins as HRP (horseradish peroxidase), alkaline phosphatase, colloid gold, FITC (poly L-lysine-fluorescein isothiocyanate), RITC (rhodamine-B-isothiocyanate, and dye, etc.

[0081] In this method, the chromogenic substrate solution can be used according to the marker, which is exemplified by TMB (3,3',5,5'-tetramethyl bezidine), ABTS [2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)], and OPD (o-phenylenediamine), etc. At this time, the chromogenic substrate is preferably provided as dissolved in buffer (0.1M NaOAc, pH 5.5).

[0082] The washing solution herein preferably includes phosphate buffer, NaCl, and Tween 20, and is more preferably the buffer (PBST) composed of 0.02 M phosphate buffer, 0.13 M NaCl, and 0.05% tween 20. This washing solution is added to the fixture after the reaction of secondary antibody with the antigen-antibody conjugate, followed by washing 3 - 6 times, but not always limited thereto. As the reaction terminating solution, sulfuric acid solution can be used.

[0083] According to the present invention, early diagnosis or prognosis of inflammatory disease can be possible by detecting CD93 or its soluble fragment by antigen-antibody reaction using the antibody specifically binding to CD93 or its soluble fragment in biological sample. The biological sample herein is selected from the group consisting of tissue, cell, blood, serum, peritoneal lavage fluid, synovial fluid, saliva, urine, and feces, but not always limited thereto. Particularly, CD93 or its soluble fragment included in a biological sample is fragmented by SDS-PAGE, and the resultant fragment is transferred onto the fixture. The antibody specifically binding to the fixed CD93 or its soluble fragment is added to induce antigen/antibody reaction. Then, the expression of CD93 or its soluble fragment is measured. If the expression of CD93 or its soluble fragment in the biological sample is high, it can be diagnosed as inflammatory disease or high risk of getting inflammatory disease.

[0084] In this method, the fixture used for antigen-antibody reaction can be nitrocellulose membrane, PVDF membrane (polyvinylidene difluoride membrane), 96-well plate made of polyvinyl resin or polystyrene resin, and glass slide glass, etc.

[0085] In this method, the antigen/antibody reaction can be measured by the conventional ELISA, radioimmunoassay (RIA), sandwich ELISA, Northern blotting, Western blotting, immunoprecipitation, immunohistochemical staining, immunofluorescence method, enzyme-substrate colorimetric method, antigen-antibody agglutination, SPR (surface plasmon resonance), biochip (DNA, RNA), electrophoresis, PCR, and RT-PCR, etc.

[0086] Practical and presently preferred embodiments of the present invention are illustrative as shown in the following Examples, Experimental Examples and Manufacturing Examples.

[0087] However, it will be appreciated that those skilled in the art, on consideration of this disclosure, may make modifications and improvements within the spirit and scope of the present invention.

<Example 1> Preparation of sCD93 protein

<1-1> Construction of pYW600

<1-1-1> Insertion of oriP

[0088] First, to clone oriP, PCR was performed using pMEP4 (Invitrogen, USA) as a template with a forward primer (5'-gtagatctgcaggaaaaggacaagc-3'; SEQ. ID. NO: 27) and a reverse primer (5'-cgagatctggtgacttcctaagt-3'; SEQ. ID. NO: 28) with the cycle of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 1 minute (30 cycles). Then, 2187 bp PCR product was purified by using PCR purification kit (Promega, USA). Next, the PCR product was digested with *Bg*III (Invitrogen, USA), and the fragment was purified. The purified fragment was inserted into the *Bg*III recognition site located upstream of CMV promoter of pcDNA3.1 (Invitrogen, USA) linearized by *Bg*III (Invitrogen, USA). Transformant (pcDNA3.1-oriP) was obtained by transfecting *E. coli* with the vector. From the transformant, plasmid was extracted by the conventional method. Then, the insertion of oriP was confirmed by nucleotide sequencing.

<1-1-2> Insertion of polynucleotide encoding human antibody Fc

[0089] To insert polynucleotide encoding human antibody Fc into pcDNA3.1 vector in which oriP was introduced, PCR was performed using pLCN-MoH vector (Korean Patent No. 450266) as a template with a forward primer (5'-cgg gat cc g gcc gtg ggg gcc gac aaa a ct cac aca tgc c-3'; SEQ. ID. NO: 29) composed of 'Bam HI-SfiI-human immunoglobulin

Fc N-terminal sequence' and a reverse primer (5'-cgagtc tca ttt acc cgg aga cag gga-3'; SEQ. ID. NO: 30) composed of 'XbaI-stop codon-human immunoglobulin Fc C-terminal sequence' as follows: 94 °C for 4 minutes; 95 °C for 30 seconds, 60 °C for 30 seconds, 72 °C for 1 minute, 30 cycles; and final extension at 72 °C for 10 minutes.

[0090] Then, the PCR product was purified by using PCR purification kit (Promega, USA). The fragment was inserted in pcDNA3.1-oriP vector predigested with *Bam*HI and *Xba*I, resulting in the construction of pcDNA3.1-oriP-Fc. *E. coli* (DH5a) was transfected with the constructed recombinant plasmid. Then, the resultant transformant was isolated. Plasmid was extracted and investigated to confirm whether or not the polynucleotide encoding Fc was correctly inserted. As a result, pYW600 was constructed.

<1-1-3> expression and purification of sCD93-Fc

[0091] To express/purify sCD93_Fc in the animal cell line HEK293E, an expression vector capable of expressing sCD93_Fc was constructed.

[0092] The constructed pYW600 containing human IgG1 Fc fragment was digested with *Sfi*I, to which CD93 fragment obtained by PCR and digested with *Sfi*I was inserted. To amplify CD93 fragment, PCR was performed using CD93 plasmid (Kugi, hMU003993, Kugi No. IRAT-49-A06) as a template with a forward primer (5'-CAGGGGGCCGT-GGGGGCCACGGGAGCTGACACGGAGGC-3'; SEQ. ID. NO: 31) and a reverse primer (5'-TAGCGGCCGACGCG-GCCAAGTCCACACAGTCCAGCTGAC-3'; SEQ. ID. NO: 32). For the PCR, 100 ng of the template, 10 pmol of each primer, and 0.5 ul of Pfu DNA polymerase (2.5 unit/ul) were used. Total volume of the reaction mixture was 50 ul. The conditions for CD93 PCR were as follows: predenaturation at 94 °C for 2 minutes, denaturation at 94 °C for 30 seconds, annealing at 55 °C for 30 seconds, polymerization at 72 °C for 1 minute, 30 cycles from denaturation to polymerization, and final extension at 72 °C for 10 minutes. The PCR product was digested with *Sfi*I, which was inserted in pYK 602 vector wherein CMV I.E enhancer/promoter, leader sequence, CD93 gene, 6X His tag, Fc, Myc, and 8X His tag were sequentially located. As a result, pYK-CD93_Fc vector was constructed.

[0093] 20 μg of the pCD93_Fc constructed above was mixed with 40 μg of polyethylenimine (PEI, Polysciences), which was introduced in HEK293E cells grown in 150 mm dish in advance. The culture medium was collected every other day for 8 days, followed by filtering. The filtrate was purified using protein A sepharose (Amersham). The purified sample was quantified by PEIRCE (Coomassie protein assay reagent), and the size was investigated on SDS-PAGE gel (Figure 2). As reduced (R), sCD93_Fc was 70 kDa and as non-reduced (N) it was 140 ~ 150 kDa.

<Example 2> Induction of differentiation of THP-1 cells into macrophages by sCD93 protein

[0094] THP-1 cells, the human originated acute monocytic leukemia cells, are eventually differentiated into macrophages via adherence, spreading, and maturation by chemical substances such as PMA, etc. In this experiment, induction of THP-1 cell differentiation into macrophages by sCD93 was investigated.

[0095] First, 5×10^3 THP-1 cells (purchased from ATCC) were distributed in 96-well plate. Negative control THP-1 cells were treated with PBS, Fc (5 μg/ml), and normal human IgG (hIgG, 5 μg/ml). Positive control THP-1 cells were treated with PMA (Sigma, 0.1 μg/ml). Experimental group THP-1 cells were treated with sCD93_Fc at the different concentrations of 5, 1, 0.2, and 0.04 μg/ml. After the treatment, they stayed in 37 °C incubator for 30 minutes. Then, all the groups were taken out to eliminate non-attached cells with tapping carefully not to lose any attached cells. After washing twice with PBS, photographs were taken under optical microscope (Leika) (Figure 3). Non-attached cells in the culture supernatant were counted using hemacytometer (Marienfeld, Germany). Non-attached cell number was subtracted from the original cell number and the produced number was presented as %. THP-1 cells were not attached in the negative control, but highly attached in the experimental group treated with sCD93_Fc dose-dependently (presented by %) (Figure 4).

[0096] Next, effect of sCD93_Fc on THP-1 cell differentiation was investigated by the same manner as described hereinbefore. Particularly, negative control THP-1 cells were treated with PBS(-) and 5 μg/ml of hIgG. Positive control THP-1 cells were treated with 0.1 μg/ml of PMA. Experimental group THP-1 cells were treated with 5 μg/ml of sCD93_Fc. Each group was cultured for three days, followed by taking pictures under optical microscope. Differentiation was not induced in the negative control. THP-1 cells treated with sCD93_Fc were differentiated to macrophage-like cells similarly to the cells treated with PMA (Figure 5).

[0097] To investigate whether THP-1 cells, the human mononuclear cells, were actually differentiated to macrophages, real-time PCR was performed to measure RNA expressions of CD14, CD1a and CD64, the markers of macrophages, dendrites, and neutrophils. Negative control THP-1 cells were treated with PBS(-) and 5 μg/ml of hIgG, and positive control THP-1 cells were treated with 0.1 μg/ml of PMA. Experimental group THP-1 cells were treated with 5 μg/ml of sCD93_Fc. 24 hours later, LPS was treated thereto to investigate susceptibility. 24 hours after the treatment, RNA was extracted and purified (Qiagen RNA miniprep kit). 1 μg of the purified RNA proceeded to reverse transcription (iScript cDNA synthesis kit, Bio-Rad) to synthesize cDNA. Quantitative-PCR was performed using the synthesized cDNA, the primers shown in Table 1, and iG SYBR Green supermix (Bio-Rad) with CFX-96 Real-time system (Bio-Rad).

EP 2 392 352 A2

[0098] As a result, it was confirmed that THP-1 cells could be differentiated to macrophages by the treatment of sCD93. In the meantime, LPS treatment triggered the increase of CD14 RNA, the differentiation marker (Figure 6).

[Table 1]

Primer sequence		
Differentiation Marker	Forward	Reverse
CD14-New	GCCTAGACCTCAGCCACAAC TC (SEQ. ID. NO: 5)	CCAGCCCAGCGAACGACAG (SEQ. ID. NO: 6)
CD64-New	GGGTCAGCGTGTTC AAGAG G (SEQ. ID. NO: 7)	GCACCTGTATTTCACCACTGTCATT G (SEQ. ID. NO: 8)
CD1a-New	ACT CAT ACC TGG GAC AGC AAT (SEQ. ID. NO: 9)	CTG CAA TTC ATG GGC GTA TCT (SEQ. ID. NO: 10)

<Example 3> Induction of mitogen-activated protein kinase (MAPK) activity by sCD93 protein

[0099] To investigate molecular action involved in THP-1 cell differentiation, MAPK (mitogen-activated protein kinase) signaling pathway was investigated.

[0100] Particularly, negative control THP-1 cells were treated with PBS(-), 5 µg/ml of Fc, and 5 µg/ml of hIgG. Positive control THP-1 cells were treated with 0.1 µg/ml of PMA. Experimental group THP-1 cells were treated with sCD93_Fc at the different concentrations of 5, 1, 0.2, and 0.04 µg/ml. They were stayed in 37°C incubator for 30 minutes after the treatment. Then, the cells were lysed by lysis buffer, followed by Western blotting. For the blotting, phospho-Erk 1/2 (cell signaling) and phospho-p38 (cell signaling) were used as primary antibodies (cell signaling), and total-p38 (cell signaling) was used for quantification. As a result, it was confirmed that phospho-Erk 1/2 and phospho-p38 were increased by sCD93_Fc dose dependently (Figure 7).

[0101] To observe changes of phospho-Erk 1/2 level over the time, THP-1 cells were treated with 5 µg/ml of sCD93_Fc for 0, 10, 30, 60, and 180 minutes respectively by the same manner as described above, followed by Western blotting. Positive control THP-1 cells were treated with 0.1 µg/ml of PMA and 1 µg/ml of LPS by the same manner as described above, followed by Western blotting. From 10 minutes after the treatment of sCD93_Fc, phospho-Erk 1/2 level began to increase and when 30 minutes passed, the increase reached top. From 60 minutes after the treatment, the level began to slightly decrease (Figure 8).

[0102] To investigate cytokine changes according to THP-1 differentiation and MAPK signaling changes, expressions of various pro-inflammatory cytokines were measured at RNA level. Particularly, negative control THP-1 cells were treated with PBS(-) and 5 µg/ml of hIgG. Positive control THP-1 cells were treated with 0.1 µg/ml of PMA. In the meantime, experimental group THP-1 cells were treated with sCD93_Fc. 24 hours later, LPS was treated thereto to investigate LPS susceptibility. 24 hours after the treatment, RNA was extracted and purified (Qiagen RNA miniprep kit). 1 µg of the purified RNA proceeded to reverse transcription (iScript cDNA synthesis kit, Bio-Rad) to synthesize cDNA. Quantitative-PCR was performed using the synthesized cDNA, the primers shown in Table 2, and iG SYBR Green supermix (Bio-Rad) with CFX-96 Real-time system (Bio-Rad).

[0103] As a result, sCD93_Fc treatment caused the increase of pro-inflammatory cytokines TNF-α, IL-1b, and IL-6 at RNA level and this increase was more significant when LPS was additionally treated thereto (Figures 9 - 11).

[Table 2]

Primer sequence		
Cytokine	Forward	Reverse
IL-6	TGG CTG AAA AAG ATG GAT GCT (SEQ. ID. NO: 11)	TCT GGC TTG TTC CTC ACT ACT (SEQ. ID. NO: 12)

(continued)

Primer sequence		
Cytokine	Forward	Reverse
5 IL-12	TGT ACC AGG TGG AGT TCA AGA (SEQ. ID. NO: 13)	GGA GGA TTT TTG TGG CAC AGT (SEQ. ID. NO: 14)
10 iNOS	ATC TTG CCT GGG GTC CAT TAT (SEQ. ID. NO: 15)	CCT GGC CAG ATG TTC CTC TAT (SEQ. ID. NO: 16)
15 CXCL11	CCT GGG GTA AAA GCA GTG AAA (SEQ. ID. NO: 17)	TTG CTT GCT TCG ATT TGG GAT (SEQ. ID. NO: 18)
20 CLEC4A	TTG GCA AGA CAG TGA GAA GGA (SEQ. ID. NO: 19)	AAT GTC GCT GAC CTT CTG GAT (SEQ. ID. NO: 20)
25 SPHK-1	CTG TAG GAA GAG TGG GTT CCA (SEQ. ID. NO: 21)	GTG CCA GGA CTA GCA CAA AG (SEQ. ID. NO: 22)
30 IL-1 β	ACA GCT GGA GAG TGT AGA TCC (SEQ. ID. NO: 23)	TTT TCT GCT TGA GAG GTG CTG (SEQ. ID. NO: 24)
35 TNF- α	TAG CCC ATG TTG TAG CAA ACC (SEQ. ID. NO: 25)	AGA GGA CCT GGG AGT AGA TGA (SEQ. ID. NO: 26)

[0104] Next, changes of TNF- α expression at protein level was investigated according to THP-1 cell differentiation and MAPK signaling changes.

[0105] Particularly, negative control THP-1 cells were treated with PBS(-) and 5 μ g/ml of hlgG. Positive control THP-1 cells were treated with 0.1 μ g/ml of PMA. In the meantime, experimental group THP-1 cells were treated with sCD93_Fc. 24 hours later, LPS was treated thereto to investigate LPS susceptibility. 24 hours after the LPS treatment, TNF- α level in the culture supernatant was measured by using Quantikine TNF- α assay kit (R&D system). As a result, TNF- α was slightly increased in the experimental group treated with sCD93_Fc alone, while TNF- α was significantly increased in the experimental group treated with both sCD93_Fc and LPS together. This result indicates that THP-1 cells were differentiated to macrophages by the treatment of sCD93_Fc with increasing susceptibility to TLR signal (Figure 12).

<Example 4> Induction of matrix metalloproteinase (MMP) expression by sCD93 protein

[0106] Effect of sCD93_Fc on matrix metalloproteinase (MMP) expression in THP-1 cells was investigated. Particularly, negative control THP-1 cells were treated with 5 μ g/ml of hlgG, while positive control THP-1 cells were treated with 0.1 μ g/ml of PMA. In the meantime experimental group THP-1 cells were treated with sCD93_Fc at the different concentrations of 5, 1, and 0.2 μ g/ml. 24 hours after the treatment, Gelatin Zymography assay was performed to investigate expressions of MMP9 (92 kDa) and MMP-2 (72 kDa) in the culture supernatant. The supernatant obtained from 24 hour culture was electrophoresed on 8% SDS-PAGE gel containing 2 mg/ml of gelatin (Sigma). Then, the gel was stained with Coomassie blue. The gel was destained with destaining solution, followed by taking pictures.

[0107] As a result, MMP-9 level was increased by the treatment of sCD_Fc dose-dependently (Figure 13).

<Example 5> Induction of phagocytosis by sCD93 protein

[0108] Phagocytosis was measured using *E. coli* expressing mRFP to investigate phagocytosis activity according to the differentiation of THP-1 cells to macrophage-like cells. Particularly, THP-1 cells were treated with 5 µg/ml of sCD93_Fc, followed by culture for 3 days. Pre-cultured *E. coli* transformed with RFP (red fluorescent protein) expression vector were added to the differentiated THP-1 cells. 12 hours later, phagocytosis of *E. coli* by THP-1 cells was confirmed under fluorescent microscope (Figure 14). Those cells were isolated by using cell dissociation buffer (EDTA buffer), which proceeded to FACS (Coulter) (Figure 15).

[0109] As a result, phagocytosis in the differentiated cells by the treatment of sCD93_Fc was far greater with showing fluorescence than in the negative control cells treated with hlgG.

<Example 6> Inhibition of TNF- α production by CD93 protein antibody

[0110] To investigate the possibility of development of an anti-inflammatory agent using the antibody against sCD93_Fc based on its effect on inflammation and differentiation, THP-1 cells were treated with anti-CD93 antibody, and the effect on inflammation and differentiation was examined (Figure 16). Particularly, negative control THP-1 cells were treated with PBS(-) and 5 µg/ml of hlgG. Positive control THP-1 cells were treated with 0.1 µg/ml of PMA. In the meantime, experimental group THP-1 cells were treated with 5 µg/ml of sCD93_Fc and 10 µg/ml of anti-CD93 polyclonal antibody (R&D system). 24 hours later, 1 µg/ml of LPS was treated thereto to investigate LPS susceptibility. 24 hours after the LPS treatment, the amount of TNF- α in the culture supernatant was measured by using Quantikine TNF- α assay kit (R&D system).

[0111] As a result, the amount of TNF- α was slightly increased in the experimental group treated with sCD93_Fc alone. In the meantime, TNF- α level was higher in the experimental group treated with both sCD93_Fc and LPS together than in the experimental group treated with LPS alone. However, the treatment of anti-CD93 antibody inhibited such increase of TNF- α at least 50 ~ 60%.

<Examples 7> Expressions of various pro-inflammatory cytokines investigated by using siRNA

[0112] CD93 in THP-1 was knock-downed by using CD93 siRNA, and changes of various cytokines were investigated by real-time PCR.

[0113] First, 2 x 10⁵ THP-1 cells (medium: 10% FBS (Hyclone) + RPMI1640 (Hyclone)) were distributed in 24-well plate, to which 1 µl of Lipofectamine RNAiMax (Invitrogen) and 10 pmol of CD93 siRNA (siCD93, Bioneer) were added, which stood for 10 minutes to induce transfection of the THP-1 cells. For negative control, negative control siRNA (Bioneer) was used. For positive control, full-length CD93 (CD93_Full) gene (Kugi, hMU003993, Kugi No. IRAT-49-A06) was used, followed by transfection by the same manner as described above. The cells were cultured for 12 hours in CO₂ incubator, followed by LPS treatment. The cells were cultured for 12 more hours. Real-time PCR was performed with TNF- α and IL-6 by the same manner as described in Examples 2 and 3.

[0114] As a result, levels of the two pro-inflammatory cytokines TNF- α and IL-6 were decreased by the treatment of siCD93. The increase by LPS treatment was also decreased. On the other hand, the levels of TNF- α and IL-6 were increased in the experiment group treated with CD93_Full. The levels of TNF- α and IL-6 were more increased by the treatment of LPS (Figure 17).

<Exantple 8> CD93 expression and CD93 soluble fragment level in THP-1 cells, the human mononuclear cells

[0115] To investigate the expression of CD93 and its fragmentation by various inflammation inducing substances or under inflammation environment, CD93 expression in THP-1 cells, the human mononuclear cells, and CD93 soluble fragment level in the culture supernatant were measured.

<8-1> CD93 expression in THP-1 cells, the human mononuclear cells: FACS

[0116] THP-1 cells were cultured in RPMI 1640 supplemented with 10% FBS, penicillin G (100 IU/M ℓ), streptomycin (100 µg/M ℓ), L-glutamine (2 mM), HEPES (10 mM), and sodium pyruvate (1.0 mM) in a 37°C incubator. The cultured THP-1 cells were treated with PBS, LPS (1.0 µg/M ℓ), TNF- α (0.5 µg/M ℓ) or PMA (0.1 µg/M ℓ) for 24 hours, followed by fixation in 4% paraformaldehyde for 20 minutes. After washing with PBS once, blocking was performed with 3% NGS (normal goat serum) for 30 minutes, followed by washing three times. The cells were reacted with ice-cold goat anti-human CD93 antibody (R&D systems) for 1 hour. After washing with PBS three times again, the cells were reacted with ice-cold anti-goat IgG-FITC antibody for 1 hour for fluorescence staining. Control groups were treated with anti-CD14-FITC antibody respectively for fluorescence staining. The stained cells were analyzed by flow cytometry (EPICS Elite,

Coulter).

[0117] As a result, as shown in Figure 18, CD93 expression on the cell surface of THP-1 was increased by LPS and TNF- α but hardly increased by PMA (Figure 18). The expression of CD14 used for the control group on the cell surface was decreased by LPS, TNF- α , and PMA, which was assumed to be attributed to CD14 fragmentation. CD14 fragmentation has been known as an important mechanism in down-modulation of monocyte-macrophage activation (Schutt, C. 1999. Cd14. *Int. J. Biochem. Cell Biol.* 31:545. 23. Le-Barillec, K., M. Si-Tahar, V. Balloy, and M. Chignard. 1999. Proteolysis of monocyte CD14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation. *J. Clin. Invest.* 103:1039. Bazil, V., and J. L. Strominger. 1991. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. *J. Immunol.* 147:1567). According to many previous research results, collagenase, neutrophil elastase, and cathepsin G can induce fragmentation of CD14 on cell surface (Bryniarski, K., K. Maresz, M. Szczepanik, M. Ptak, and W. Ptak. 2003. Modulation of macrophage activity by proteolytic enzymes. Differential regulation of IL-6 and reactive oxygen intermediates (ROTs) synthesis as a possible homeostatic mechanism in the control of inflammation. *Inflammation* 27:333. Le-Barillec, K., M. Si-Tahar, V. Balloy, and M. Chignard. 1999. Proteolysis of monocyte CD14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation. *J. Clin. Invest.* 103:1039. Coyne, C. P., T. Howell III, H. Smodlaka, C. Willetto, B. W. Fenwick, and E. Chenney. 2002. Alterations in membrane-associated CD14 expression and the simultaneous liberation of soluble CD14 fragment in adherent macrophages mediated by a leukocyte carboxyl/aspartate protease. *J. Endotoxin. Res.* 8:273.).

<8-2> Western blotting

[0118] THP-1 cells were cultured in RPMI 1640 supplemented with 10% FBS, penicillin G (100 IU/M ℓ), streptomycin (100 μ g/M ℓ), L-glutamine (2 mM), HEPES (10 mM), and sodium pyruvate (1.0 mM) in a 370 \square incubator. After treating the cultured THP-1 cells with PBS, LPS (1.0 μ g/M ℓ), TNF- α (0.5 μ g/M ℓ) or PMA (0.1 μ g/M ℓ) for 24 hours, lysate and supernatant were obtained. The samples were boiled for 5 minutes and frozen for storage. After loading the samples on 8% SDS-PAGE gel, electrophoresis was performed. The gel was transferred onto nitrocellulose membrane, followed by blocking with 4% skim milk. The gel was reacted with goat anti-CD93 antibody (0.5 μ g/M ℓ , R&D systems) at room temperature for 1 hour. After washing with PBST three times, the gel was reacted with anti-goat IgG-HRP antibody (0.5 μ g/M ℓ , Santa Cruz) at room temperature for 1 hour. As internal controls, anti- β actin (Santa Cruz) and anti-goat IgG-HRP (Santa Cruz) were used. Experiment was performed using ECL kit (ECL Plus, Amersham, USA) according to the manufacturer's instructions.

[0119] As a result, as shown in Figure 19, the expression of CD93 itself was increased by the treatment of LPS and TNF- α , which was consistent with the result of FACS, but it was not increased by the treatment of PMA. In the meantime, the expression of CD93 soluble fragment was increased by the treatment of LPS, TNF- α and even PMA (Figure 19). The above results indicate that not only CD93 itself but also CD93 soluble fragment are up-regulated in inflammation condition or by inflammation inducing substances in THP-1 and Jukat cells. Therefore, CD93 or its soluble fragment is expected to be an effective diagnostic marker for inflammatory disease.

<8-3> RT-PCR

[0120] THP-1 cells were cultured in 6 well-plate, and then treated with PBS, LPS (1.0 μ g/M ℓ , InvivoGen), and PMA (0.1 μ g/M ℓ , Sigma) respectively. 24 hours after the treatment, RNA was identified by using RNA identification kit (Qiagen). For reverse transcription, reverse transcriptase (Bio-Rad) and dNTP were mixed, leading to reaction for one hour at 42 \square to obtain cDNA of each. For real-time PCR, CFX96 system (Bio-Rad) was used. PCR was performed as follows: pre-denaturation at 95 \square for 3 minutes, annealing at 95 \square for 15 seconds, polymerization at 60 \square for 1 minute, 40 ~ 45 cycles. Fluorescence was measured at each annealing stage and data was recorded automatically stage by stage. Particularly, 2 μ l of cDNA template and CD93 primer were mixed with 23 iQ SYBR Supermix (Bio-Rad) for reaction. Every reaction was repeated twice. To measure the relative mRNA expression, average threshold cycle (Ct) value was set as standard value. Every Ct value was standardized by GAPDH. Primer sets used herein are as follows: CD93: forward primer CTC TGG GGC TAC TGG TCT ATC (SEQ. ID. NO: 34), reverse primer TGT CGG ACT GTA CTG GTT CTC (SEQ. ID. NO: 35); GAPDH: forward primer CAT GTT CGT CAT GGG TGT GAA (SEQ. ID. NO: 36), reverse primer GGA

[0121] CTG TGG TCA TGA GTC CTT (SEQ. ID. NO: 37).

[0122] As a result, as shown in Figure 20, CD93 expression in THP-1 cells was significantly increased by the treatment of LPS and PMA (Figure 20).

<Example 9> CD93 expression in mouse peripheral blood mononuclear cells and peritoneal cells and quantification, of CD93 soluble fragment in serum and peritoneal lavage fluid (*in vivo*)

[0123] Like the above *in vitro* quantification of CD93 expression, *in vivo* experiment was performed as follows to investigate CD93 expression and fragmentation thereof. Particularly, peritonitis was induced in the test mouse or inflammation inducing substance (thioglycollate or LPS) was injected to the mouse. Then, CD93 expression in the mouse peripheral blood mononuclear cells and peritoneal cells was investigated and at the same time the amount of CD93 soluble fragment in serum and peritoneal lavage fluid (PLF) was measured.

<9-1> CD93 expression in mouse peripheral blood mononuclear cells and peritoneal cells: FACS

[0124] Balb/c mice at 6 weeks of age were injected with 1 Ml of PBS, 4% thioglycollate or 0.1 mg/Ml of LPS. Three days later, blood was drawn from retro-orbital vein of the mice using heparin-coated glass capillary tube. Then, serum and PBMC cells were obtained by centrifugation. After scarifying the mice, peritoneal lavage fluid (PLF) and peritoneal cells (mostly intraabdominal macrophages) were obtained from the abdominal cavity. To eliminate red blood cells from the cells, 10 Ml of red blood cell lysing buffer (Sigma) was added, followed by reaction twice at 37°C, resulting in the complete elimination of red blood cells. Fluorescence staining was performed by the same manner as described in Example <8-1>. At that time, anti-mouse CD93 antibody (R&D systems) and anti-goat IgG-FITC (Santa Cruz) were used. To investigate macrophage differentiation, double staining was performed by using CD11b antibody (BD Sciences), the differentiation marker.

[0125] As a result, as shown in Figure 21, CD93 expression in macrophages of peritoneal cells of the mouse was significantly increased by the treatment of LPS. The expression was similarly increased by the treatment of thioglycollate (Figure 21). Therefore, it was confirmed that macrophages existing in PBMCs were moved into peritoneal fluid by the treatment of thioglycollate and LPS.

<9-2> Western blotting

[0126] The remaining half of the cells not used in Example <9-1> was lysed, followed by Western blotting. Western blotting was performed by the same manner as described in Example <8-2> except that sheep anti-mouse CD93 antibody (R&D systems) and anti-sheep IgG-HRP (Santa Cruz) were used to detect mouse CD93. To investigate macrophage differentiation, double staining was performed by using CD11b antibody (BD Sciences), the differentiation marker. As internal controls, anti-β actin (Santa Cruz) and anti-goat IgG-HRP (Santa Cruz) were used. Experiment was performed using ECL kit (ECL Plus, Amersham, USA) according to the manufacturer's instructions.

[0127] As a result, as shown in Figure 22, CD93 expression was significantly increased in mouse peritoneal cells by the treatment of thioglycollate and LPS (Figure 22), which was consistent with the result of FACS above.

<9-3> Quantification of CD93 soluble fragment: Sandwich ELISA

[0128] After confirming by FACS and Western blotting that the amount of CD93 molecule itself was increased, the inventors further investigated the changes of CD93 soluble fragment. Particularly, the amount of CD93 soluble fragment in serum and peritoneal lavage fluid (PLF) was measured by sandwich ELISA.

[0129] First, 96-well falcon plate (Becton Dickinson) was coated with rat anti-mouse CD93 antibody (R&D Systems) at the concentration of 100 ng/well for overnight. After washing the plate with PBST three times, blocking was performed with 3% skim milk at room temperature for 30 minutes. After washing the plate with PBST three times again, each of mouse serum and peritoneal lavage fluid was loaded thereto (100 μl/well), which stood for 2 hours. As standard material for quantification, mouse CD93 soluble fragment was used. After washing the plate 3 times, 1 μg/Ml of sheep anti-mouse CD93 antibody (R&D systems) was added thereto, which stood for 1 hour. One μg/Ml of anti-sheep IgG-HRP antibody (Santa Cruz) was added thereto, followed by reaction for 1 hour. After washing the plate with PBST three times again, color development was induced by using OPD (Sigma). OD was measured by using spectrophotometer (VER-SAmx tunable microplate reader, Molecular Devices). Absolute quantification was performed with the measured value using standard curve.

[0130] As a result, as shown in Figure 23, the amount of CD93 soluble fragment in serum was hardly changed by the treatment of LPS or thioglycollate. However, the amount of CD93 soluble fragment in peritoneal lavage fluid was significantly increased by the treatment of LPS or thioglycollate (Figure 23). Therefore, it was suggested that CD93 soluble fragment could be effectively used as a diagnostic marker for inflammatory disease.

<Example 10> CD93 expression in synovial membrane tissue and quantification of CD93 soluble fragment in synovial fluid**<10-1> CD93 expression in synovial membrane tissue: immunohistochemistry**

5
[0131] Synovial membrane (synovium) tissues were obtained from three rheumatoid-arthritis (RA) patients and 2 osteo-arthritis (OA) patients, which were fixed in 4% paraformaldehyde for overnight. The tissues were dehydrated with alcohol and embedded in paraffin, followed by sectioning. To eliminate peroxidase activity therein, the tissues were reacted with methanolic H₂O₂. To eliminate non-specific reaction, blocking was performed with 3% NGS (normal goat serum for 2 hours. The tissues were reacted with goat anti-human CD93 antibody (R&D), viotinylated anti-goat IgG, and streptavidine-peroxidase complex (Vector, Peterborough, UK) stepwise for 1 hour each. The tissues were counter-stained with hematoxyline, followed by observation under Olympus microscope (Tokyo, Japan).

10
[0132] As a result, as shown in Figure 24, CD93 up-regulation was more significant in synovial membrane tissues obtained from rheumatoid arthritis patients than in synovial membrane tissues from osteo-arthritis patients (Figure 24).
15 Particularly, CD93 expression was significantly increased in synovial lining where lymphocytes are infiltrated, sublining, and perivascular region.

<10-2> Quantification of CD93 soluble fragment in synovial fluid: Sandwich ELISA

20 [0133] The amount of CD93 soluble fragment in synovial fluid obtained from 8 rheumatoid arthritis patients and 8 osteo-arthritis patients was measured by sandwich ELISA.

[0134] First, 93-well falcon plate (Becton Dickinson) was coated with rat anti-human CD93 antibody (R&D Systems) at the concentration of 100 ng/well for overnight. After washing the plate with PBST three times, blocking was performed with 3% skim milk at room temperature for 30 minutes. After washing the plate with PBST three times again, each of
25 synovial fluid (SF) obtained from 8 rheumatoid arthritis patients and 8 osteo-arthritis patients was loaded thereto (100 μℓ/well), which stood for 2 hours. As standard material for quantification, human soluble CD93 was used. After washing the plate with 3 times, 1 μg/Mℓ of goat anti-human CD93 antibody (R&D systems) was added thereto, which stood for 1 hour. One μg/Mℓ of anti-goat IgG-HPR antibody (Santa Cruz) was added thereto, followed by reaction for 1 hour. After washing the plate with PBST three times again, color development was induced by using OPD (Sigma). OD was measured
30 by suing spectrophotometer. Absolute quantification was performed with the measured value using standard curve.

[0135] As a result, as shown in Figure 25, the amount of CD93 soluble fragment in synovial fluid obtained from rheumatoid arthritis patients was significantly higher than that in synovial fluid obtained from osteo-arthritis patients (Figure 25).

35 [0136] Therefore, it was suggested that CD93 molecule or its soluble fragment could be effectively used as a diagnostic marker for inflammatory disease.

[Industrial Applicability]

40 [0137] As explained hereinbefore, the present invention can be effectively used for the development of a therapeutic agent and a diagnostic kit for various inflammatory diseases.

[0138] Those skilled in the art will appreciate that the conceptions and specific embodiments disclosed in the foregoing description may be readily utilized as a basis for modifying or designing other embodiments for carrying out the same purposes of the present invention. Those skilled in the art will also appreciate that such equivalent embodiments do not depart from the spirit and scope of the invention as set forth in the appended Claims.
45

50

55

SEQUENCE LISTING

5 <110> Korea Research Institute of Bioscience and Biotechnology
 PARK, Young Woo
 JEON, Jae Won
 JUNG, Joon-Goo
 CHOI, Hye In
 SOHN, Myung-ho
 10 KIM, Ho youn
 CHO, Mi-La
 JANG, Young-Soon
 MOON, Ji-Hun
 PARK, Ji Hyun

<120> Use of CD93 or soluble fragment thereof

15 <130> 11fpo-07-06_us

<150> KR10-2009-0006592
 <151> 2009-01-28

20 <150> KR10-2009-0116723
 <151> 2009-11-30

<160> 37

<170> PatentIn version 3.5

25 <210> 1
 <211> 325
 <212> PRT
 <213> Homo sapiens

<400> 1

30 Gly Thr Gly Ala Asp Thr Glu Ala Val Val Cys Val Gly Thr Ala Cys
 1 5 10 15

Tyr Thr Ala His Ser Gly Lys Leu Ser Ala Ala Glu Ala Gln Asn His
 20 25 30

35 Cys Asn Gln Asn Gly Gly Asn Leu Ala Thr Val Lys Ser Lys Glu Glu
 35 40 45

40 Ala Gln His Val Gln Arg Val Leu Ala Gln Leu Leu Arg Arg Glu Ala
 50 55 60

Ala Leu Thr Ala Arg Met Ser Lys Phe Trp Ile Gly Leu Gln Arg Glu
 65 70 75 80

45 Lys Gly Lys Cys Leu Asp Pro Ser Leu Pro Leu Lys Gly Phe Ser Trp
 85 90 95

50 Val Gly Gly Gly Glu Asp Thr Pro Tyr Ser Asn Trp His Lys Glu Leu
 100 105 110

Arg Asn Ser Cys Ile Ser Lys Arg Cys Val Ser Leu Leu Leu Asp Leu
 115 120 125

55 Ser Gln Pro Leu Leu Pro Ser Arg Leu Pro Lys Trp Ser Glu Gly Pro

EP 2 392 352 A2

130 135 140

5 Cys Gly Ser Pro Gly Ser Pro Gly Ser Asn Ile Glu Gly Phe Val Cys
145 150 155 160

Lys Phe Ser Phe Lys Gly Met Cys Arg Pro Leu Ala Leu Gly Gly Pro
165 170 175

10 Gly Gln Val Thr Tyr Thr Thr Pro Phe Gln Thr Thr Ser Ser Ser Leu
180 185 190

Glu Ala Val Pro Phe Ala Ser Ala Ala Asn Val Ala Cys Gly Glu Gly
15 195 200 205

Asp Lys Asp Glu Thr Gln Ser His Tyr Phe Leu Cys Lys Glu Lys Ala
210 215 220

20 Pro Asp Val Phe Asp Trp Gly Ser Ser Gly Pro Leu Cys Val Ser Pro
225 230 235 240

Lys Tyr Gly Cys Asn Phe Asn Asn Gly Gly Cys His Gln Asp Cys Phe
245 250 255

25 Glu Gly Gly Asp Gly Ser Phe Leu Cys Gly Cys Arg Pro Gly Phe Arg
260 265 270

Leu Leu Asp Asp Leu Val Thr Cys Ala Ser Arg Asn Pro Cys Ser Ser
30 275 280 285

Ser Pro Cys Arg Gly Gly Ala Thr Cys Val Leu Gly Pro His Gly Lys
290 295 300

35 Asn Tyr Thr Cys Arg Cys Pro Gln Gly Tyr Gln Leu Asp Ser Ser Gln
305 310 315 320

Leu Asp Cys Val Asp
325

40

<210> 2
<211> 975
<212> DNA
<213> Homo sapiens

45 <400> 2
ccccttgagg cccagctggg agccgagata gaagctcctg tcgccgctgg gcttctcgcc 60
tccgcagag ggccacacag agaccgggat ggccacctc atgggctgc tgctgctgct 120
gctgctgctc ctgaccagc ccggggcggg gacgggagct gacacggagg cggtggtctg 180
50 cgtggggacc gctgctaca cggcccactc gggcaagctg agcgtgccg aggccagaa 240
cactgcaac cagaacgggg gcaacctggc cactgtgaag agcaaggagg aggccagca 300
cgtccagcga gtactggecc agctcctgag gcgggaggca gccctgacgg cgaggatgag 360

55

EP 2 392 352 A2

caagttctgg attgggctcc agcgagagaa gggcaagtgc ctggacccta gtctgccgct 420
5 gaagggcttc agctgggtgg gcggggggga ggacacgcct tactctaact ggcacaagga 480
gctccggaac tcgtgcatct ccaagcgctg tgtgtctctg ctgctggacc tgtcccagcc 540
gctccttccc agccgcctcc ccaagtggtc tgagggcccc tgtgggagcc caggetcccc 600
10 cggaagtaac attgagggct tcgtgtgcaa gttcagcttc aaaggcatgt gccggcctct 660
ggccttgggg ggcccaggtc aggtgaccta caccaccccc ttccagacca ccagttcctc 720
cttgaggct gtgccctttg cctctgcggc caatgtagcc tgtggggaag gtgacaagga 780
15 cgagactcag agtcattatt tcctgtgcaa ggagaaggcc cccgatgtgt tcgactgggg 840
cagctcgggc cccctctgtg tcagcccaaa gtatggctgc aacttcaaca atgggggctg 900
ccaccaggac tgcttgaag ggggggatgg ctccttcctc tgcggctgcc gaccaggatt 960
20 ccggctgctg gatga 975

<210> 3
<211> 652
<212> PRT
<213> Homo sapiens

25 <400> 3
Met Ala Thr Ser Met Gly Leu Leu Leu Leu Leu Leu Leu Leu Thr
1 5 10 15
30 Gln Pro Gly Ala Gly Thr Gly Ala Asp Thr Glu Ala Val Val Cys Val
20 25 30
Gly Thr Ala Cys Tyr Thr Ala His Ser Gly Lys Leu Ser Ala Ala Glu
35 35 40 45
Ala Gln Asn His Cys Asn Gln Asn Gly Gly Asn Leu Ala Thr Val Lys
50 55 60
40 Ser Lys Glu Glu Ala Gln His Val Gln Arg Val Leu Ala Gln Leu Leu
65 70 75 80
Arg Arg Glu Ala Ala Leu Thr Ala Arg Met Ser Lys Phe Trp Ile Gly
85 90 95
45 Leu Gln Arg Glu Lys Gly Lys Cys Leu Asp Pro Ser Leu Pro Leu Lys
100 105 110
50 Gly Phe Ser Trp Val Gly Gly Gly Glu Asp Thr Pro Tyr Ser Asn Trp
115 120 125
His Lys Glu Leu Arg Asn Ser Cys Ile Ser Lys Arg Cys Val Ser Leu
130 135 140
55 Leu Leu Asp Leu Ser Gln Pro Leu Leu Pro Ser Arg Leu Pro Lys Trp

EP 2 392 352 A2

420 425 430

5 Gly Pro Gly Gly Pro Leu Cys Asp Ser Leu Cys Phe Asn Thr Gln Gly
435 440 445

10 Ser Phe His Cys Gly Cys Leu Pro Gly Trp Val Leu Ala Pro Asn Gly
450 455 460

15 Val Ser Cys Thr Met Gly Pro Val Ser Leu Gly Pro Pro Ser Gly Pro
465 470 475 480

20 Pro Asp Glu Glu Asp Lys Gly Glu Lys Glu Gly Ser Thr Val Pro Arg
485 490 495

25 Ala Ala Thr Ala Ser Pro Thr Arg Gly Pro Glu Gly Thr Pro Lys Ala
500 505 510

30 Thr Pro Thr Thr Ser Arg Pro Ser Leu Ser Ser Asp Ala Pro Ile Thr
515 520 525

35 Ser Ala Pro Leu Lys Met Leu Ala Pro Ser Gly Ser Pro Gly Val Trp
530 535 540

40 Arg Glu Pro Ser Ile His His Ala Thr Ala Ala Ser Gly Pro Gln Glu
545 550 555 560

45 Pro Ala Gly Gly Asp Ser Ser Val Ala Thr Gln Asn Asn Asp Gly Thr
565 570 575

50 Asp Gly Gln Lys Leu Leu Leu Phe Tyr Ile Leu Gly Thr Val Val Ala
580 585 590

55 Ile Leu Leu Leu Leu Ala Leu Ala Leu Gly Leu Leu Val Tyr Arg Lys
595 600 605

60 Arg Arg Ala Lys Arg Glu Glu Lys Lys Glu Lys Lys Pro Gln Asn Ala
610 615 620

65 Ala Asp Ser Tyr Ser Trp Val Pro Glu Arg Ala Glu Ser Arg Ala Met
625 630 635 640

70 Glu Asn Gln Tyr Ser Pro Thr Pro Gly Thr Asp Cys
645 650

<210> 4
 <211> 6701
 <212> DNA
 <213> Homo sapiens

<400> 4
 aaagccctca gccttttgtt ctttctctgc gccggagtgg ctgcagctca cccctcagct 60
 cccttgggg cccagctggg agccgagata gaagctcctg tcgccgctgg gcttctcgcc 120

EP 2 392 352 A2

tcccgcagag ggccacacag agaccgggat ggccacctcc atgggcctgc tgctgctgct 180
 5 gctgctgctc ctgacccagc ccggggcggg gacgggagct gacacggagg cgggtggtctg 240
 cgtggggacc gcctgctaca cggcccactc gggcaagctg agcgcctgcc aggccccagaa 300
 ccaactgcaac cagaacgggg gcaacctggc cactgtgaag agcaaggagg aggccccagca 360
 10 cgtccagcga gtactgcccc agctcctgag gcgggaggca gccctgacgg cgaggatgag 420
 caagtctctg attgggctcc agcgagagaa gggcaagtgc ctggacccta gtctgccgct 480
 gaagggcttc agctgggtgg gcggggggga ggacacgcct tactctaact ggcacaagga 540
 gctccggaac tcgtgcatct ccaagcgtg tggtgtctctg ctgctggacc tgtcccagcc 600
 15 gctccttccc agccgcctcc ccaagtggtc tgagggcccc tgtgggagcc caggctcccc 660
 cggaagtaac attgagggct tcgtgtgcaa gttcagcttc aaaggcatgt gccggcctct 720
 ggccctgggg ggcccaggtc aggtgacctc caccacccc ttccagacca ccagttctc 780
 20 ctggaggct gtgccctttg cctctgcggc caatgtagcc tgtggggaag gtgacaagga 840
 cgagactcag agtcattatt tcctgtgcaa ggagaaggcc cccgatgtgt tcgactgggg 900
 cagctcgggc cccctctgtg tcagcccaa gtatggctgc aactcaaca atgggggctg 960
 25 ccaccaggac tgcttgaag ggggggatgg ctcttctc tcggctgcc gaccaggatt 1020
 ccggctgctg gatgacctgg tgacctgtgc ctctgaaac ccttgacgt ccagcccatg 1080
 tcgtgggggg gccactgcy tcctgggacc ccatgggaaa aactacacgt gccgctgccc 1140
 ccaagggtac cagctggact cgagtcagct ggactgtgtg gacgtggatg aatgccagga 1200
 30 ctccccctgt gcccaggagt gtgtcaacac ccctgggggc ttccgctgcy aatgctgggt 1260
 tggctatgag ccgggcggtc ctggagaggg ggcctgtcag gatgtggatg agtgtgctct 1320
 gggctgctcg ccttgcgccc agggctgcac caacacagat ggctcatttc actgctctg 1380
 35 tgaggagggc tacgtcctgg ccggggagga cgggactcag tgccaggacg tggatgagtg 1440
 tgtgggcccg gggggcccc tctgcgacag cttgtgttc aacacacaag ggtccttcca 1500
 ctgtggctgc ctgccaggct ggggtgctggc ccaaatggg gtctcttgca ccatggggcc 1560
 40 tgtgtctctg ggaccaccat ctgggcccc cgatgaggag gacaaaggag agaaagaagg 1620
 gagcaccgtg ccccgctgcy caacagccag tcccacaagg gggcccagg gcacccccaa 1680
 ggctacaccc accacaagta gacctcgt gtcactgac gccccatca catctgcccc 1740
 45 actcaagatg ctggccccca gtgggtcccc aggcgtctgg agggagccca gcatccatca 1800
 cgccacagct gcctctggcc cccaggagcc tgcagggtgg gactcctccg tggccacaca 1860
 aaacaacgat ggactgacg ggcaaaagct gcttttattc tacatcctag gcaccgtgg 1920
 50 ggccatccta ctctgctgg ccctggctct ggggctactg gtctatcgca agcggagagc 1980
 gaagagggag gagaagaagg agaagaagcc ccagaatgcy gcagacagtt actcctgggt 2040
 tccagagcga gctgagagca gggccatgga gaaccagtac agtccgacac ctgggacaga 2100
 ctgctgaaag tgagggtggc ctagagacac tagagtcacc agccaccatc ctgagagctt 2160

55

EP 2 392 352 A2

tgaactccc attccaaagg ggcaccaca ttttttgaa agactggact ggaatcttag 2220
 5 caaacaattg taagtctcct ccttaaaggc cccttggaac atgcaggat tttctacggg 2280
 tgtttgatgt tcctgaagtg gaagctgtgt gttggcgtgc cacggtgggg atttcgtgac 2340
 tctataatga ttgttactcc ccctcccttt tcaaattcca atgtgaccaa ttccggatca 2400
 10 ggggtgtgagg aggccggggc taaggggctc ccctgaatat cttctctgct cacttccacc 2460
 atctaagagg aaaaggtgag ttgctcatgc tgattaggat tgaaatgatt tgtttctctt 2520
 cctaggatga aaactaaatc aattaattat tcaattagggt aagaagatct ggttttttgg 2580
 15 tcaaagggaa catgttcgga ctggaacat ttctttacat ttgcattcct ccatttcgcc 2640
 agcacaagtc ttgctaaatg tgatactggt gacatcctcc agaatggcca gaagtgcaat 2700
 taacctcta ggtggcaagg aggcaggaag tgcctcttta gttcttcat ttctaatagc 2760
 cttgggttta ttgcaaagg aagctgaaa aatatgagaa aagttgcttg aagtgcatta 2820
 20 cagggtgtttg tgaagtcaca taatctacgg ggctagggcg agagaggcca gggatttgtt 2880
 cacagatact tgaattaatt catccaatg tactgagggt accacacact tgactacgga 2940
 tgtgatcaac actaacaagg aaacaattc aaggacaacc tgtctttgag ccagggcagg 3000
 25 cctcagacac cctgcctgtg gccccgctc cacttcatcc tgcccggaat gccagtgctc 3060
 cgagctcaga cagaggaagc cctgcagaaa gttccatcag gctgtttcct aaaggatgtg 3120
 tgaacgggag atgatgcaact gtgttttgaa agttgtcatt ttaaagcatt ttagcacagt 3180
 30 tcatagtcca cagttgatgc agcatcctga gattttaaat cctgaagtgt ggggtggcgca 3240
 cacaccaagt agggagctag tcaggcagtt tgcttaagga acttttgctc tctgtctctt 3300
 ttccttaaaa ttgggggtaa ggaggggaagg aagagggaaa gagatgacta actaaaatca 3360
 35 tttttacagc aaaaactgct caaagccatt taaattatat cctcatttta aaagttacat 3420
 ttgcaaatat ttctccctat gataatgtag tcgatagtgt gcaactcttc tctctctctc 3480
 tctctctcac acacacacac acacacacac acacacacac agagacacgg caccattctg 3540
 40 cctggggcac tggaacacat tcctgggggt caccgatggt cagagtcact agaagttacc 3600
 tgagtatctc tgggaggcct catgtctcct gtgggctttt taccaccact gtgcaggaga 3660
 acagacagag gaaatgtgtc tcctccaag gcccacaagc ctcagagaaa ggggtgttct 3720
 45 ggttttgctc tagcaatgca tcggtctctg aggtgacact ctggagtggg tgaagggcca 3780
 caaggtgcag ggttaatact cttgccagtt ttgaaatata gatgctatgg ttcagattgt 3840
 ttttaataga aaactaaagg ggcaggggaa gtgaaaggaa agatggagggt tttgtgcggc 3900
 50 tcgatggggc atttggaaact tctttttaa gtcatctcat ggtctccagt tttcagttgg 3960
 aactctggtg ttaacactt aaggagaca aaggctgtgt ccatttggca aaacttcctt 4020
 ggccacgaga ctctaggtga tgtgtgaagc tgggcagtct gtggtgtgga gagcagccat 4080
 ctgtctggcc attcagagga ttctaaagac atggctggat gcgctgctga ccaacatcag 4140
 55 cacttaataa aatgcaaatg caacatttct ccctctgggc cttgaaaatc cttgccctta 4200

EP 2 392 352 A2

tcatttgggg tgaaggagac atttctgtcc ttggcttccc acagcccca cgcagtctgt 4260
 5 gtatgattcc tgggatccaa cgagccctcc tattttcaca gtgttctgat tgctctcaca 4320
 gcccaggccc atcgtctgtt ctctgaatgc agccctgttc tcaacaacag ggaggatcatg 4380
 gaaccctctt gtggaaccca caaggggaga aatgggtgat aaagaatcca gttcctcaaa 4440
 10 accttccctg gcaggctggg tccctctcct gctgggtggg gctttctctt gcacaccact 4500
 cccaccacgg ggggagagcc agcaacccaa ccagacagct caggttgtgc atctgatgga 4560
 aaccactggg ctcaaacacg tgctttattc tcctgtttat ttttgctggt actttgaagc 4620
 atggaaattc ttgtttgggg gatcttgggg ctacagtagt gggtaaacaa atgcccaccg 4680
 15 gccaaagaggc cattaacaaa tcgtccttgt cctgaggggc cccagcttgc tcgggcgtgg 4740
 cacagtgggg aatccaaggg tcacagtatg gggagaggtg caccctgcca cctgctaact 4800
 tctcgctaga cacagtgttt ctgccaggt gacctgttca gcagcagaac aagccagggc 4860
 20 catggggacg ggggaagttt tcaactggag atggacacca agacaatgaa gatttgttgt 4920
 ccaaataaggc caataattct gggagactct tggaaaaaac tgaatatatt caggaccaac 4980
 tctctccctc ccctcatccc acatctcaaa gcagacaatg taaagagaga acatctcaca 5040
 25 caccagctc gccatgccta ctattctctg aatttcagggt gccatcactg ctctttcttt 5100
 cttctttgtc atttgagaaa ggatgcagga ggacaattcc cacagataat ctgaggaatg 5160
 cagaaaaacc agggcaggac agttatcgac aatgcattag aacttgggtga gcacccctctg 5220
 tagagggact ccaccctgc tcaacagctt ggcttccagg caagaccaac cacatctggt 5280
 30 ctctgccttc ggtggccac acacctaagc gtcacgtca ttgccatagc atcatgatgc 5340
 aacacatcta cgtgtagcac tacgacgta tgtttgggta atgtggggat gaactgcatg 5400
 aggctctgat taaggatgtg gggaggtggg ctgaggctac tgtcggcctt gcaaggccac 5460
 35 ctggaggcct gtctgttagc cagtgggtgga ggagcaaggc ttcaggaagg gccagccaca 5520
 tgccatctc cctgcgatca ggcaaaaaag tggaaattaa aagtcaaacc tttatatgca 5580
 tgtgttatgt ccattttgca ggatgaactg agtttaaaag aatttttttt tctcttcaag 5640
 40 ttgctttgtc ttttccatcc tcatcacaag cccttgtttg agtgtcttat ccctgagcaa 5700
 tctttcgatg gatggagatg atcattaggt acttttgttt caacctttat tctgttaaat 5760
 atttctgtga aaactaggag aacagagatg agatttgaca aaaaaaatt gaattaaaaa 5820
 45 taacacagtc tttttaaacc taacatagga aagcctttc tattatttct cttcttagct 5880
 tctccattgt ctaaatacag aaaaacaggaa aacacagctt tctagcagct gcaaaatggt 5940
 ttaatgcccc ctacatattt ccatcacctt gaacaatagc tttagcttgg gaatctgaga 6000
 tatgatccca gaaaacatct gtctctactt cggctgcaaa acccatgggt taaatctata 6060
 50 tggtttgtgc attttctcaa ctaaaaatag agatgataat ccgaattctc catatattca 6120
 ctaatcaaag aactattttt catactagat tcctgagaca aatactcact gaagggtctg 6180
 tttaaaaata aattgtgttt tggctctgtt ttgtagataa tgcccttcta ttttaggtag 6240

55

EP 2 392 352 A2

aagctctgga atccctttat tgtgctgttg ctcttatctg caaggtggca agcagttctt 6300
 5 ttcagcagat ttgcccact attcctctga gctgaagttc ttgcataga ttggccttaa 6360
 gcttgaatta gatccctgca aaggcttgct ctgtgatgct agatgtaatt gtaaagtca 6420
 gtaatcactt catgaatgct aatgagaat gtaagtattt taaatgtgt gtatttcaaa 6480
 10 ttgtttgac taattctgga attacaagat ttctatgcag gatttacctt catcctgtgc 6540
 atgtttcca aactgtgagg agggaaggct cagagatcga gcttcctc tgagttctaa 6600
 caaatggtg ctttgagggt cagccttag gaaggtgcag cttgttgct ctttgagctt 6660
 15 tctgttatgt gcctatccta ataaactctt aaacacattg a 6701

<210> 5
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> CD14-New forward primer

<400> 5
 gcctagacct cagccacaac tc 22

<210> 6
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> CD14-New reverse primer

<400> 6
 ccagcccagc gaacgacag 19

<210> 7
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> CD64-New forward primer

<400> 7
 gggtcagcgt gttccaagag g 21

<210> 8
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> CD64-New reverse primer

<400> 8
 gcacctgat tcaccactgt cattg 25

<210> 9
 <211> 21

<212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> CD1a-New forward primer
 <400> 9
 actcataacct gggacagcaa t 21

10 <210> 10
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> CD1a-New reverse primer
 <400> 10
 ctgcaattca tgggcgtatc t 21

20 <210> 11
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> IL-6 forward primer
 25 <400> 11
 tggctgaaaa agatggatgc t 21

30 <210> 12
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> IL-6 reverse primer
 35 <400> 12
 tctggcttgt tcctcactac t 21

40 <210> 13
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> IL-12 forward primer
 45 <400> 13
 tgtaccaggt ggagttcaag a 21

50 <210> 14
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> IL-12 reverse primer
 55 <400> 14
 ggaggatfff tgtggcacag t 21

5 <210> 15
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> iNOS forward primer

10 <400> 15
 atcttgctg gggccatta t 21

<210> 16
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> iNOS reverse primer

20 <400> 16
 cctggccaga tgctcctta t 21

<210> 17
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> CXCL11 forward primer

30 <400> 17
 cctggggtaa aagcagtgaa a 21

<210> 18
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> CXCL11 reverse primer

40 <400> 18
 ttgcttgctt cgatttggga t 21

<210> 19
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> CLEC4A forward primer

50 <400> 19
 ttggcaagac agtgagaagg a 21

<210> 20
 <211> 21
 <212> DNA
 <213> Artificial Sequence

55 <220>

<223> CLEC4A reverse primer
 <400> 20
 5 aatgctgctg accttctgga t 21

 <210> 21
 <211> 21
 <212> DNA
 <213> Artificial sequence
 10
 <220>
 <223> SPHK-1 forward primer

 <400> 21
 15 ctgtaggaag agtgggttcc a 21

 <210> 22
 <211> 20
 <212> DNA
 <213> Artificial sequence
 20
 <220>
 <223> SPHK-1 reverse primer

 <400> 22
 25 gtgccaggac tagcacaag 20

 <210> 23
 <211> 21
 <212> DNA
 <213> Artificial sequence
 30
 <220>
 <223> IL-1 beta forward primer

 <400> 23
 35 acagctggag agttagatc c 21

 <210> 24
 <211> 21
 <212> DNA
 <213> Artificial sequence
 40
 <220>
 <223> IL-1 beta reverse primer

 <400> 24
 45 ttttctgctt gagaggtgct g 21

 <210> 25
 <211> 21
 <212> DNA
 <213> Artificial sequence
 50
 <220>
 <223> TNF-alpha forward primer

 <400> 25
 tagcccatgt tntagcaaac c 21

 <210> 26
 <211> 21
 55

EP 2 392 352 A2

<212> DNA
 <213> Artificial Sequence
 5 <220>
 <223> TNF-alpha reverse primer
 <400> 26
 agaggacctg ggagtagatg a 21
 10 <210> 27
 <211> 25
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> pMEP4 forward primer
 <400> 27
 gtagatctgc aggaaaagga caagc 25
 20 <210> 28
 <211> 26
 <212> DNA
 <213> Artificial Sequence
 25 <220>
 <223> pMEP4 reverse primer
 <400> 28
 cgagatctgg ttgacttccc taatgt 26
 30 <210> 29
 <211> 40
 <212> DNA
 <213> Artificial Sequence
 35 <220>
 <223> Bam HI SfiI human immunoglobulin Fc N terminal sequence forward
 primer
 <400> 29
 cgggatccgg ccgtgggggc cgacaaaact cacacatgcc 40
 40 <210> 30
 <211> 27
 <212> DNA
 <213> Artificial Sequence
 45 <220>
 <223> XbaI stop codon human immunoglobulin Fc C terminal sequence
 reverse primer
 <400> 30
 cgagtctcat ttaccggag acagga 27
 50 <210> 31
 <211> 38
 <212> DNA
 <213> Artificial Sequence
 55 <220>
 <223> CD93 plasmid forward primer

EP 2 392 352 A2

<400> 31
cagggggccg tgggggccac gggagctgac acggaggc 38

5 <210> 32
<211> 39
<212> DNA
<213> Artificial sequence

10 <220>
<223> CD93 plasmid reverse primer

<400> 32
tagcggccga cgcgccaag tccacacagt ccagctgac 39

15 <210> 33
<211> 652
<212> PRT
<213> Homo sapiens

<400> 33

20 Met Ala Thr Ser Met Gly Leu Leu Leu Leu Leu Leu Leu Leu Thr
1 5 10 15

Gln Pro Gly Ala Gly Thr Gly Ala Asp Thr Glu Ala Val Val Cys Val
20 25 30

25 Gly Thr Ala Cys Tyr Thr Ala His Ser Gly Lys Leu Ser Ala Ala Glu
35 40 45

30 Ala Gln Asn His Cys Asn Gln Asn Gly Gly Asn Leu Ala Thr Val Lys
50 55 60

Ser Lys Glu Glu Ala Gln His Val Gln Arg Val Leu Ala Gln Leu Leu
65 70 75 80

35 Arg Arg Glu Ala Ala Leu Thr Ala Arg Met Ser Lys Phe Trp Ile Gly
85 90 95

40 Leu Gln Arg Glu Lys Gly Lys Cys Leu Asp Pro Ser Leu Pro Leu Lys
100 105 110

Gly Phe Ser Trp Val Gly Gly Gly Glu Asp Thr Pro Tyr Ser Asn Trp
115 120 125

45 His Lys Glu Leu Arg Asn Ser Cys Ile Ser Lys Arg Cys Val Ser Leu
130 135 140

Leu Leu Asp Leu Ser Gln Pro Leu Leu Pro Ser Arg Leu Pro Lys Trp
145 150 155 160

50 Ser Glu Gly Pro Cys Gly Ser Pro Gly Ser Pro Gly Ser Asn Ile Glu
165 170 175

Gly Phe Val Cys Lys Phe Ser Phe Lys Gly Met Cys Arg Pro Leu Ala

55

EP 2 392 352 A2

180 185 190
 5 Leu Gly Gly Pro Gly Gln Val Thr Tyr Thr Thr Pro Phe Gln Thr Thr
 195 200 205
 Ser Ser Ser Leu Glu Ala Val Pro Phe Ala Ser Ala Ala Asn Val Ala
 210 215 220
 10 Cys Gly Glu Gly Asp Lys Asp Glu Thr Gln Ser His Tyr Phe Leu Cys
 225 230 235 240
 Lys Glu Lys Ala Pro Asp Val Phe Asp Trp Gly Ser Ser Gly Pro Leu
 245 250 255
 Cys Val Ser Pro Lys Tyr Gly Cys Asn Phe Asn Asn Gly Gly Cys His
 260 265 270
 20 Gln Asp Cys Phe Glu Gly Gly Asp Gly Ser Phe Leu Cys Gly Cys Arg
 275 280 285
 Pro Gly Phe Arg Leu Leu Asp Asp Leu Val Thr Cys Ala Ser Arg Asn
 290 295 300
 25 Pro Cys Ser Ser Ser Pro Cys Arg Gly Gly Ala Thr Cys Val Leu Gly
 305 310 315 320
 30 Pro His Gly Lys Asn Tyr Thr Cys Arg Cys Pro Gln Gly Tyr Gln Leu
 325 330 335
 Asp Ser Ser Gln Leu Asp Cys Val Asp Val Asp Glu Cys Gln Asp Ser
 340 345 350
 35 Pro Cys Ala Gln Glu Cys Val Asn Thr Pro Gly Gly Phe Arg Cys Glu
 355 360 365
 40 Cys Trp Val Gly Tyr Glu Pro Gly Gly Pro Gly Glu Gly Ala Cys Gln
 370 375 380
 Asp Val Asp Glu Cys Ala Leu Gly Arg Ser Pro Cys Ala Gln Gly Cys
 385 390 395 400
 45 Thr Asn Thr Asp Gly Ser Phe His Cys Ser Cys Glu Glu Gly Tyr Val
 405 410 415
 Leu Ala Gly Glu Asp Gly Thr Gln Cys Gln Asp Val Asp Glu Cys Val
 420 425 430
 50 Gly Pro Gly Gly Pro Leu Cys Asp Ser Leu Cys Phe Asn Thr Gln Gly
 435 440 445
 55 Ser Phe His Cys Gly Cys Leu Pro Gly Trp Val Leu Ala Pro Asn Gly

EP 2 392 352 A2

450 455 460
 5 Val Ser Cys Thr Met Gly Pro Val Ser Leu Gly Pro Pro Ser Gly Pro
 465 470 475 480
 Pro Asp Glu Glu Asp Lys Gly Glu Lys Glu Gly Ser Thr Val Pro Arg
 485 490 495
 10 Ala Ala Thr Ala Ser Pro Thr Arg Gly Pro Glu Gly Thr Pro Lys Ala
 500 505 510
 Thr Pro Thr Thr Ser Arg Pro Ser Leu Ser Ser Asp Ala Pro Ile Thr
 515 520 525
 15 Ser Ala Pro Leu Lys Met Leu Ala Pro Ser Gly Ser Pro Gly Val Trp
 530 535 540
 20 Arg Glu Pro Ser Ile His His Ala Thr Ala Ala Ser Gly Pro Gln Glu
 545 550 555
 Pro Ala Gly Gly Asp Ser Ser Val Ala Thr Gln Asn Asn Asp Gly Thr
 565 570 575
 25 Asp Gly Gln Lys Leu Leu Leu Phe Tyr Ile Leu Gly Thr Val Val Ala
 580 585 590
 30 Ile Leu Leu Leu Leu Ala Leu Ala Leu Gly Leu Leu Val Tyr Arg Lys
 595 600 605
 Arg Arg Ala Lys Arg Glu Glu Lys Lys Glu Lys Lys Pro Gln Asn Ala
 610 615 620
 35 Ala Asp Ser Tyr Ser Trp Val Pro Glu Arg Ala Glu Ser Arg Ala Met
 625 630 635 640
 Glu Asn Gln Tyr Ser Pro Thr Pro Gly Thr Asp Cys
 645 650
 40 <210> 34
 <211> 21
 <212> DNA
 <213> Artificial sequence
 45 <220>
 <223> CD93 forward primer
 <400> 34
 ctctggggct actggtctat c 21
 50 <210> 35
 <211> 21
 <212> DNA
 <213> Artificial sequence
 55

<220>
 <223> CD93 reverse prime
 5 <400> 35
 tgtcggactg tactggttct c 21

 <210> 36
 <211> 21
 <212> DNA
 10 <213> Artificial sequence

 <220>
 <223> GAPDH forward primer
 15 <400> 36
 catgttcgtc atgggtgtga a 21

 <210> 37
 <211> 21
 <212> DNA
 20 <213> Artificial sequence

 <220>
 <223> GAPDH reverse primer
 25 <400> 37
 ggactgtggt catgagtcct t 21

Claims

- 30 1. An anti-inflammatory composition containing CD93 soluble fragment specific antibody composed of the amino acid sequence represented by SEQ. ID. NO: 1 as an active ingredient.
- 35 2. The anti-inflammatory composition according to claim 1, wherein the antibody is one or more antibodies selected from the group consisting of monoclonal antibody, polyclonal antibody, multispecific antibody, humanized antibody, human antibody, antibody fragment, recombinant antibody, and chemically modified antibody.
- 40 3. The anti-inflammatory composition according to claim 2, wherein the antibody fragment is selected from the group consisting of Fab, F(ab'), F(ab')₂, scFv, Fv, Fab/c, antibody fragments obtained by treating antibody with protease, and those antibodies obtained by genetic recombination technique.
- 45 4. The anti-inflammatory composition according to claim 1, wherein the antibody is monoclonal antibody or polyclonal antibody.
- 50 5. The anti-inflammatory composition according to claim 4, wherein the monoclonal antibody is prepared by the method comprising the following steps:
 1) immunizing mammals with an immunogen selected from the group consisting of sCD93, sCD93 fragment, and full-length CD93, and collecting the antibody producing cells;
 2) constructing hybridoma by fusion of the antibody producing cells and myeloma cells; and
 3) obtaining monoclonal antibody from the hybridoma.
- 55 6. The anti-inflammatory composition according to claim 4, wherein the polyclonal antibody is prepared by the method comprising the following steps:
 1) immunizing mammals with an immunogen selected from the group consisting of sCD93, sCD93 fragment, and full-length CD93;
 2) isolating sCD93 specific antibody from blood taken from the immunized mammals.

EP 2 392 352 A2

7. An anti-inflammatory composition containing one or more substances selected from the group consisting of siRNA, shRNA, and shRNA expression vector capable of suppressing CD93 gene expression composed of the nucleotide sequence represented by SEQ. ID. NO: 4 as an active ingredient.
- 5 8. A method for treating inflammation containing the step of administering either the composition of claim 1 or the composition of claim 7 to a subject with inflammation.
9. A method for preventing inflammation containing the step of administering either the composition of claim 1 or the composition of claim 7 to a subject.
- 10 10. A use of the antibody of claim 1 or one of the substances of claim 7 selected from the group consisting of siRNA, shRNA, and shRNA expression vector for the preparation of the anti-inflammatory composition.
11. A diagnostic kit for inflammatory disease comprising CD93 or its soluble fragment specific antibody or aptamer.
- 15 12. The diagnostic kit for inflammatory disease according to claim 11, wherein the soluble fragment is the 95kDa ectodomain of CD93 protein released after cell culture.
13. The diagnostic kit for inflammatory disease according to claim 11, wherein the inflammatory disease is the one selected from the group consisting of asthma, allergic and non-allergic rhinitis, acute and chronic rhinitis, acute and chronic gastritis or enteritis, ulcerative gastritis, acute and chronic nephritis, acute and chronic hepatitis, chronic obstructive pulmonary disease, pulmonary fibrosis, irritable bowel syndrome, inflammatory pain, migraine, headache, lumbago, fibromyalgia, myofascial disease, viral infection, bacterial infection, fungal infection, burn, wound by surgical or dental operation, hyper-prostaglandin E syndrome, atherosclerosis, gout, arthritis, rheumatoid arthritis, ankylosing spondylitis, Hodgkin's disease, pancreatitis, conjunctivitis, iritis, scleritis, uveitis, dermatitis, eczema, and multiple sclerosis.
- 25 14. A diagnostic method for inflammatory disease comprising the following steps:
- 30 1) coating biological sample and control protein on a fixture;
2) inducing antigen-antibody reaction by adding the antibody specifically binding to CD93 or its soluble fragment having the amino acid sequence represented by SEQ. ID. NO: 33 to the above fixture;
3) detecting the antigen-antibody reaction product produced by the above antigen-antibody reaction by using a secondary antibody conjugate marker and chromogenic substrate solution;
35 4) comparing the detection results between the biological sample and the control; and
5) Diagnosing inflammatory disease or high risk of inflammatory disease when CD93 or its soluble fragment is up-regulated in the biological sample, compared with the level in the control.
15. The diagnostic method for inflammatory disease according to claim 14, wherein the biological sample is one or more substances selected from the group consisting of tissue, cell, blood, serum, peritoneal lavage fluid, synovial fluid, saliva, urine, and feces.
- 40 16. The diagnostic method for inflammatory disease according to claim 14, wherein the fixture is the one selected from the group consisting of nitrocellulose membrane, PVDF membrane (polyvinylidene difluoride membrane), 96-well plate made of polyvinyl resin or polystyrene resin, and glass slide glass.
- 45 17. The diagnostic method for inflammatory disease according to claim 14, wherein the antigen-antibody reaction is measured by the method selected from the group consisting of ELISA, radioimmunoassay (RIA), sandwich ELISA, Northern blotting, Western blotting, immunoprecipitation, immunohistochemical staining, immunofluorescence method, enzyme-substrate colorimetric method, antigen-antibody agglutination, SPR (surface plasmon resonance), biochip (DNA, RNA), electrophoresis, PCR, and RT-PCR.
- 50 18. The diagnostic method for inflammatory disease according to claim 14, wherein the secondary antibody conjugate marker is the one selected from the group consisting of HRP (horseradish peroxidase), alkaline phosphatase, colloid gold, FITC (poly L-lysine-fluorescein isothiocyanate), RITC (rhodamine-B-isothiocyanate), and dye.
- 55 19. The diagnostic method for inflammatory disease according to claim 14, wherein the chromogenic substrate solution is the one selected from the group consisting of TMB (3,3',5,5'-tetramethyl bezidine), ABTS [2,2'-azino-bis(3-ethyl-

EP 2 392 352 A2

benzothiazoline-6-sulfonic acid)], and OPD (o-phenylenediamine).

- 20.** A use of the antibody or aptamer specifically binding to CD93 or its soluble fragment for the preparation of the diagnostic kit for inflammatory disease.

5

10

15

20

25

30

35

40

45

50

55

[Fig. 1]


A

1 MATSMGLLLL LLLLLTQPGA GTGADTEAVV CVGTACYTAH SGKLSAAEAQ NHCNQNGGNL
 61 ATVKSKEEAQ HVQRVLAQLL RREAALTARM SKFWIGLQRE KGKCLDPSLP LKGFVWVGGG
 121 EDTPYSNWHK ELRNSCISKR CVSLLLDLSQ PLLPSRLPKW SEGPCGSPGS PGSNIEGFVC
 181 KFSFKGMCRP LALGGPGQVT YTPPFQTSS SLEAVPFASA ANVACGEGDK DETQSHYFLC
 241 KEKAPDVFDW GSSGPLCVSP KYGCNFNNGG CHQDCFEGGD GSFLCGCRPG FRLLDDLVT
 301 ASRNPCCSSP CRGGATCVLG PHGKNYTCRC PQGYQLDSSQ LDCVDVDECQ DSPCAQECVN
 361 TPGGFRCECW VGYEPGGPGE GACQDVDECA LGRSPCAQGC TNTDGSFHCS CEEGYVLAGE
 421 DGTQCQDVDE CVGPGGPLCD SLCFNTQGSF HCGCLPGWVL APNGVSCTMG PVS LGPPSPG
 481 PDEEDKGEKE GSTVPRAATA SPTRGPEGTP KATPTTSRPS LSSDAPITSA PLKMLAPSGS
 541 PGVWREPSIH HATAASGPQE PAGGDSSVAT QNNDGTDGQK LLLFYILGTV VAILLLLALA
 601 LGLLVYRKRK AKREEKKEKK PQNAADSYSW VPERAESRAM ENQYSPTPGT DC


B

**24GTGADTEAVV CVGTACYTAH SGKLSAAEAQ NHCNQNGGNL ATVKS
 EEAQ HVQRVLAQLL RREAALTARM SKFWIGLQRE KGKCLDPSLP LKGF
 VVGGGEDTPYSNWHK ELRNSCISKR CVSLLLDLSQ PLLPSRLPKW SEG
 P CGSPGSPGS NIEGFVCKFSFKGMCRP LALGGPGQVT YTPPFQTSSS
 LEA VPFASA ANVACGEGDK DETQSHYFLC KEKAPDVFDW GSSGPLCV
 SPKY GCNFNNGG CHQDCFEGGD GSFLCGCRPG FRLLDDLVT CASRNP
 CSSP CRGGATCVLG PHGKNYTCRC PQGYQLDSSQLDCVD³⁴⁵**


[Fig. 2]




[Fig. 3]




[Fig. 4]




[Fig. 5]




[Fig. 6]




[Fig. 7]




[Fig. 8]




[Fig. 9]




[Fig. 10]




[Fig. 11]




[Fig. 12]







[Fig. 14]




[Fig. 15]




[Fig. 16]




[Fig. 17]




[Fig. 18]




[Fig. 19]




[Fig. 20]



[Fig. 21]




[Fig. 22]




[Fig. 23]


sCD93 concentration in mouse serum and PLF



[Fig. 24]



[Fig. 25]



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 2008082519 A [0005]
- WO 9411523 A [0045]
- WO 200406549 A [0060]
- KR 450266 [0089]

Non-patent literature cited in the description

- Malhotra, R. et al. *Immunology*, 1993, vol. 78, 341-348 [0002]
- Nepomuceno, R. R. et al. *Immunity*, 1997, vol. 6, 119-129 [0002]
- Steinberger, P. et al. *Biol.*, 2002, vol. 71, 133-140 [0002]
- Petrenko, O. et al. *Immunity*, 1999, vol. 10, 691-700 [0002]
- Norsworthy, P. J. et al. *J. Immunol.*, 2004, vol. 172, 3406-3414 [0002] [0004]
- McGreal, E. P. et al. *J. Immunol.*, 2002, vol. 168, 5222-5232 [0002]
- Nepomuceno R. R. et al. *Immunity*, 1997, vol. 6, 119-129 [0003]
- Park, M. et al. *J. Cell Physiol*, 2003, vol. 196, 512-522 [0003]
- Nepomuceno, R. R. et al. *J. Immunol.*, vol. 162, 3583 [0003]
- Nepomuceno, R. R. et al. *Immunity*, 1997, vol. 6, 119 [0003]
- Nepomuceno, R. R. et al. *J. Immunol.*, 1998, vol. 160, 1929 [0003]
- Danet G. H. et al. *Proc Natl Acad Sci USA*, 2002, vol. 99, 10441-5 [0003]
- Lovik G. et al. *J Immunol*, 2000, vol. 30, 3355-62 [0003]
- Fonseca M. I. et al. *J Leukoc Biol*, 2001, vol. 70, 793-800 [0003]
- Webster, S. D. et al. *J. Leukocyte Biol.*, 2000, vol. 67, 109 [0003]
- Petrenko, O. et al. *Immunity*, 1999, vol. 10, 691 [0003]
- Dean, Y. D. et al. *J. Immunol.*, vol. 31, 1370 [0003]
- Fonseca, M. 1. et al. *J. Leukocyte Biol.*, 2001, vol. 70, 793 [0003]
- Nepomuceno, R. R. et al. *J. Immunol.*, 1999, vol. 162, 3583 [0003]
- McGreal, E. P. et al. *J. Immunol.*, 2002, vol. 168, 5222 [0003]
- Steinberger, P. et al. *J. Leukocyte Biol.*, 2002, vol. 71, 133 [0003]
- Guan, E. et al. *J. Immunol.*, 1994, vol. 152, 4005-4016 [0004]
- Brown, E. J. *Phagocytosis. Bioessays*, 1995, vol. 17, 109-117 [0004]
- Park, M. et al. *J. Cell Physiol.*, 2003, vol. 196, 512-522 [0005]
- Suzanne S. Bohlson et al. *J. immunol*, 2005, vol. 175, 1239-1247 [0005]
- Tamauchi H. ; Inoko H. Decrease in CD93 expression in a human monocyte-like cell line (U937) treated with various apoptosis-inducing chemical substances. *Microbiol. Immunol.*, 2007, vol. 51 (12), 1189-1200 [0005]
- Riechmann L. et al. *Nature*, 1988, vol. 332, 323-327 [0031]
- Nakatani T. et al. *Protein Engineering*, 1994, vol. 7, 435-443 [0031]
- Jones et al. *Nature*, 1986, vol. 321, 522-525 [0031]
- Presta. *Curr. Op. Struct. Biol.*, 1992, vol. 2, 593-596 [0031]
- Jakobovits et al. *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 2551 [0032]
- Jakobovits et al. *Nature*, 1993, vol. 362, 255-258 [0032]
- Bruggermann et al. *Year in Immuno.*, 1993, vol. 7, 33 [0032]
- Hoogenboom et al. *J. Mol. Biol.*, 1991, vol. 227, 381 [0032]
- Marks et al. *J. Mol. Bio.*, 1991, vol. 222, 581-597 [0032]
- Zapata et al. *Protein Eng.*, 1995, vol. 8 (10), 1057-1062 [0033]
- Vandamme, A. M. et al. *Eur. J. Biochem.*, 1990, vol. 192, 767-775 [0043]
- Chirgwin, J. M. et al. *Biochemistry*, 1979, vol. 18, 5294-5299 [0044]
- Chomczynski, P. et al. *Anal. Biochem.*, vol. 162, 156-159 [0044]
- Sambrook et al. *Molecular Cloning A Laboratory Manual*. Cold Spring Harbor Laboratory Press, 1989 [0052]
- Ausubel et al. *Current Protocols in Molecular Biology*. Jon Willey & Sons, 1993 [0052]

- **Sambrook, J. ; Russel, D.** Molecular Cloning, A LABORATORY MANUAL. Cold Spring Harbor Laboratory Press, 2001 [0052]
- *Nature*, 1998, vol. 391, 806-811 [0057]
- *Genes Dev.*, 2001, vol. 15, 485-490 [0057]
- *Nature*, 2001, vol. 411, 494-498 [0057]
- *Science*, 2000, vol. 287, 2494-2497 [0057]
- *Cell*, 2000, vol. 101, 25-33 [0057]
- *Science*, 2002, vol. 296, 1265-1269 [0057]
- *J. Biol. Chem.*, 28 February 2003, vol. 278 (9), 7108-18 [0057]
- *Proc. Natl. Acad. Sci. US A*, 2002, vol. 99 (8), 5515-5520 [0059]
- *Nature Biotechnology*, 2002, vol. 20, 505-508 [0059]
- *Nature Biotechnology*, 2002, vol. 20, 500-505 [0059]
- *Nat Cell Biol.*, 2003, vol. 5, 489-490 [0059]
- *Proc. Natl. Acad. Sci. USA*, 2002, vol. 99 (9), 6047-6052 [0059]
- **Schutt, C.** *Cd14*. *Int. J. Biochem. Cell Biol.*, 1999, vol. 31, 545 [0117]
- **Le-Barillec, K. ; M. Si-Tahar ; V. Balloy ; M. Chignard.** Proteolysis of monocyte CD14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation. *J. Clin. Invest.*, 1999, vol. 103, 1039 [0117]
- **Bazil, V. ; J. L. Strominger.** Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. *J. Immunol.*, 1991, vol. 147, 1567 [0117]
- **Bryniarski, K. ; K. Maresz ; M. Szczepanik ; M. Ptak ; W. Ptak.** Modulation of macrophage activity by proteolytic enzymes. Differential regulation of IL-6 and reactive oxygen intermediates (ROTs) synthesis as a possible homeostatic mechanism in the control of inflammation. *Inflammation*, 2003, vol. 27, 333 [0117]
- **Le-Barillec, K. ; M. Si-Tahar ; V. Balloy ; M. Chignard.** Proteolysis of monocyte CD14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation. *J. Clin. Invest.*, 1999, vol. 103, 1039 [0117]
- **Coyne, C. P. ; T. Howell III ; H. Smodlaka ; C. Willetto ; B. W. Fenwick ; E. Chenney.** Alterations in membrane-associated CD14 expression and the simultaneous liberation of soluble CD14 fragment in adherent macrophages mediated by a leukocyte carboxyl/aspartate protease. *J. Endotoxin. Res.*, 2002, vol. 8, 273 [0117]

专利名称(译)	CD93或其可溶性片段的使用		
公开(公告)号	EP2392352A4	公开(公告)日	2013-06-26
申请号	EP2010735985	申请日	2010-01-18
[标]申请(专利权)人(译)	韩国生命工学研究院		
申请(专利权)人(译)	韩国研究学院生物科学与生物		
当前申请(专利权)人(译)	韩国研究学院生物科学与生物		
[标]发明人	PARK YOUNG WOO JEON JAE WON JUNG JOON GOO CHOI HYE IN SOHN MYUNG HO KIM HO YOUN CHO MI LA JANG YOUNG SOON MOON JI HUN PARK JI HYUN		
发明人	PARK, YOUNG WOO JEON, JAE WON JUNG, JOON-GOO CHOI, HYE IN SOHN, MYUNG-HO KIM, HO YOUN CHO, MI-LA JANG, YOUNG-SOON MOON, JI-HUN PARK, JI HYUN		
IPC分类号	A61K39/395 A61K31/7105 G01N33/53 A61P29/00 A61P37/08		
CPC分类号	A61K31/7105 A61P1/00 A61P1/04 A61P1/16 A61P1/18 A61P11/00 A61P11/02 A61P11/06 A61P13/12 A61P17/00 A61P17/02 A61P19/02 A61P19/06 A61P21/00 A61P25/00 A61P25/04 A61P25/06 A61P27/02 A61P29/00 G01N33/6893 G01N2333/70596		
优先权	1020090006592 2009-01-28 KR 1020090116723 2009-11-30 KR		
其他公开文献	EP2392352A2 EP2392352B1		
外部链接	Espacenet		

摘要(译)

本发明涉及使用特异性结合CD93或其可溶性片段的抗体的抗炎组合物，以及使用CD93或其可溶性片段特异性抗体或适体的炎症疾病的诊断方法和诊断试剂盒。

